Antifolate Receptor Conjugate Cancer Therapy
The use of antibody conjugates targeting folate receptor alpha in a controlled dosing regimen addresses the need for effective cancer therapy by selectively binding to FolRα, reducing tumor size and managing side effects, thereby improving treatment outcomes.
Patent Information
- Application Number
- JP2024532202
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-04-20
- Filing Date
- 2022-11-30
- Publication Date
- 2024-11-27
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for improved therapeutic methods that coordinate immunomodulation of folate receptor alpha (FolRα or FOLR1) and downstream signaling processes for effective cancer therapy, with a focus on providing safe and targeted doses of therapeutic conjugates specifically directed to FOLR1.
A method of treating cancer using an antibody conjugate that selectively binds to folate receptor alpha (FolRα or FOLR1), administered in a specific dosing schedule with varying doses over multiple cycles, potentially combined with agents like granulocyte colony stimulating factor (GCSF) to manage side effects.
The method effectively targets cancer cells by selectively binding to folate receptor alpha, reducing tumor size and improving treatment efficacy while minimizing side effects through controlled dosing and combination therapy.
Smart Images

Figure 2024544058000001_ABST
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 264,784, filed December 1, 2021, and No. 63 / 332,973, filed April 20, 2022, the contents of which are incorporated by reference in their entirety into this specification.
[0002] FIELD OF THEINVENTION
[0002] Provided herein are cancer therapies with antibody conjugates having binding specificity for folate receptor alpha (FolRα or FOLR1) and compositions for administering same, including pharmaceutical compositions. The cancer therapies are useful in methods of treating and preventing cell proliferation and cancer. The cancer therapies are also useful in methods of treating and preventing autoimmune diseases, infectious diseases and inflammatory conditions. [Background technology]
[0003] background
[0003] Folate receptors or folate-binding proteins (FBPs) comprise single-chain glycoproteins that bind folate and other compounds in vivo and contribute to renewal. Elwood, 1989, J. Biol. Chem. 264:14893-14901. Certain folate receptors are single-chain glycoproteins with high affinity binding sites for folate and other compounds such as methotrexate. Elwood, p. 14893. The human FOLR1 gene encodes the adult folate receptor, a 30 kDa polypeptide of approximately 257 amino acids with three potential N-linked glycosylation sites. Elwood, p. 14893;Lacey et al., 1989, J. Clin. Invest. 84:715-720. Homologous genes and polypeptides have been identified in dozens of species.
[0004]
[0004] The size of the mature folate receptor glycoprotein is approximately 42 kDa and it has been observed to be involved in the internalization of folates and antifolates. Elwood et al., 1997, Biochemistry 36:1467-1478. Expression has been observed in human cerebellar and kidney cells as well as in human cancer cell lines. Elwood et al., 1997, p. 1467. In addition to internalization of folate, the folate receptor has been shown to be an important cofactor for the cell entry of viruses, particularly Marburg and Ebola viruses. Chan et al., 2001, Cell 106:117-126. Due to these internalization properties, the folate receptor has been proposed as a target for diagnostic and therapeutic agents. For example, diagnostic and therapeutic agents have been linked to folate for internalization into cells expressing the folate receptor. See, e.g., Leamon, 2008, Curr. Opin. Investig. Drugs 9:1277-1286; Paulos et al., 2004, Adv. Drug Del. Rev. 56:1205-1217.
[0005]
[0005] Folate receptor alpha (FolRα or FOLR1) is a glycosylphosphatidylinositol-linked cell surface glycoprotein with high affinity for folate. Except for low levels in kidney and lung, most normal tissues do not express FOLR1, but high levels of FOLR1 have been found in serous and endometrioid epithelial ovarian cancer, endometrioid adenocarcinoma, non-small cell lung cancer (NSCLC) of adenocarcinoma subtype, and triple-negative breast cancer (TNBC). FOLR1 expression is maintained in metastatic and recurrent cancers of ovarian cancer patients, and FOLR1 expression has been observed after chemotherapy for epithelial ovarian cancer and endometrial cancer. These properties, coupled with the very limited expression of FOLR1 on normal tissues, make FOLR1 a very promising target for cancer therapy. Thus, the folate receptor provides a potential target for the diagnosis and treatment of cancer and inflammatory conditions. Summary of the Invention [Problem to be solved by the invention]
[0006]
[0006] For therapeutic purposes, improved therapeutic methods are needed that modulate the immune regulation of folate receptor alpha (FolRα or FOLR1) and downstream signaling processes activated by folate receptor alpha (FolRα or FOLR1), in particular improved methods that provide safe and effective doses of therapeutic conjugates directed against FOLR1. [Means for solving the problem]
[0007] overview
[0007] Provided herein is a method for treating cancer in a human patient using an antibody conjugate that selectively binds to folate receptor alpha (FolRα or FOLR1) at a specific dose and with a specific administration schedule. The antibody conjugate comprises an antibody that binds to folate receptor alpha (FolRα or FOLR1) linked to one or more payload moieties. The antibody may be linked to the payload directly by a covalent bond or indirectly by a linker. Folate receptor alpha (FolRα or FOLR1) antibodies are described in detail herein, as are useful payload moieties and useful linkers.
[0008]
[0008] In one aspect, methods of using anti-FOLR1 antibody conjugates and compositions are provided herein. In certain embodiments, the methods are therapeutic methods. In certain embodiments, the conjugate is administered according to a dosing schedule. In certain embodiments, the conjugate is administered 1-3 doses at a first dose, and then at least 1-3 doses at a second dose. In certain embodiments, the first dose is higher than the second dose. In certain embodiments, the first dose is about 5.2 mg / kg. In certain embodiments, the second dose is about 4.3 mg / kg. In certain embodiments, the first dose is about 4.3 mg / kg. In certain embodiments, the second dose is about 3.5 mg / kg. In certain embodiments, the second dose is maintained for the remainder of the treatment. In certain embodiments, there is a third dose of about 3.5 mg / kg or about 2.9 mg / kg. In certain embodiments, there is a fourth dose of about 2.9 mg / kg. In certain embodiments, each new dose is lower than the previous dose. In certain embodiments, the method is used to treat a disease or condition. In certain embodiments, the disease or condition is cancer.
[0009]
[0009] In certain embodiments, provided herein is a method of treating cancer in a subject in need thereof, the method comprising the steps of administering a first dose of a folate receptor alpha (FOLR1) antibody conjugate to the subject, the FOLR1 antibody conjugate comprising an antibody linked to at least one payload moiety, the first dose being about 5.2 mg / kg; and administering a second dose of the FOLR1 antibody conjugate to the subject, the second dose being administered after the first dose, the amount of the second dose being less than the amount of the first dose, and the first and second doses being administered at least about 3 weeks apart.
[0010]
[0010] In certain embodiments, provided herein is a method of treating cancer in a subject in need thereof, the method comprising the steps of administering a first dose of a folate receptor alpha (FOLR1) antibody conjugate to the subject, the FOLR1 antibody conjugate comprising an antibody linked to at least one payload moiety, the first dose being about 4.3 mg / kg; and administering a second dose of the FOLR1 antibody conjugate to the subject, the second dose being administered after the first dose, the amount of the second dose being less than the amount of the first dose, and the first and second doses being administered at least about 3 weeks apart.
[0011]
[0011] In certain embodiments, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a first dose of a folate receptor alpha (FOLR1) antibody conjugate, where the FOLR1 antibody conjugate comprises an antibody linked to at least one payload moiety; and administering to the subject a second dose of a FOLR1 antibody conjugate, where the second dose is about 4.3 mg / kg or less, where the second dose is administered after the first dose, where the amount of the first dose is greater than the amount of the second dose, and where the first dose is administered once every three or more weeks for one to six cycles.
[0012]
[0012] In certain embodiments, the first dose is about 5.2 mg / kg, and the second dose is selected from about 4.3 mg / kg, about 3.5 mg / kg, and about 2.9 mg / kg. In certain embodiments, there is a third dose, and the third dose is selected from about 3.5 mg / kg and about 2.9 mg / kg. In certain embodiments, there is a fourth dose, and the fourth dose is about 2.9 mg / kg. In certain embodiments, the doses are about 5.2 mg / kg and about 4.3 mg / kg, in order. In certain embodiments, the doses are about 5.2 mg / kg, about 4.3 mg / kg, and about 3.5 mg / kg, in order. In certain embodiments, the doses are about 5.2 mg / kg, about 4.3 mg / kg, about 3.5 mg / kg, and about 2.9 mg / kg, in order. In certain embodiments, the doses are about 5.2 mg / kg, about 4.3 mg / kg, and about 2.9 mg / kg, in that order. In certain embodiments, the doses are about 5.2 mg / kg and about 3.5 mg / kg, in that order. In certain embodiments, the doses are about 5.2 mg / kg, about 3.5 mg / kg, and about 2.9 mg / kg, in that order. In certain embodiments, the doses are about 5.2 mg / kg and about 2.9 mg / kg, in that order. The dosing cycle is as described herein for each of the first, second, third, or fourth doses. In certain embodiments, each dose is administered about 3 weeks from the previous and next doses.
[0013]
[0013] In certain embodiments, the first dose is about 4.3 mg / kg and the second dose is selected from about 3.5 mg / kg and about 2.9 mg / kg. In certain embodiments, the first dose is about 4.3 mg / kg and the second dose is about 3.5 mg / kg. The first dose is about 4.3 mg / kg and the second dose is about 2.9 mg / kg. In certain embodiments, there is a third dose, the third dose is about 2.9 mg / kg followed by a second dose of 3.5 mg / kg and a first dose of about 4.3 mg / kg. In certain embodiments, the doses are about 4.3 mg / kg and about 3.5 mg / kg in order. In certain embodiments, the doses are about 4.3 mg / kg, about 3.5 mg / kg and about 2.9 mg / kg in order. In certain embodiments, the doses are about 4.3 mg / kg and about 2.9 mg / kg in order. The dosing cycle is as described herein for each of the first, second, or third doses, hi certain embodiments, each dose is administered about 3 weeks from the previous and next dose.
[0014]
[0014] In certain embodiments, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a first dose of a folate receptor alpha (FOLR1) antibody conjugate, where the FOLR1 antibody conjugate comprises an antibody linked to at least one payload moiety; administering to the subject a second dose of a FOLR1 antibody conjugate, where the second dose is administered after the first dose, wherein the amount of the first dose is the same as or greater than the amount of the second dose, a tumor tissue sample from the subject has a Tumor Proportion Score (TPS) of about 25% or greater, and the subject has at least 30% volumetric tumor reduction three weeks after administration of the first dose.
[0015]
[0015] In certain embodiments, the FOLR1 antibody conjugate is administered in combination with a second agent. In certain embodiments, the second agent is granulocyte colony stimulating factor (GCSF). In certain embodiments, the second agent is pegfilgrastim. In certain embodiments, the second agent is filgrastim. The second agent is administered as described herein, for example, according to label instructions. In certain embodiments, the second agent reduces the rate of neutropenia in the subject. In certain embodiments, the dose of pegfilgrastim is selected taking into account the half-life of the FOLR1 antibody conjugate, for example, starting on day 8±2 of the treatment cycle. Without intending to be bound by any particular theory of operation, it has been discovered that administration of pegfilgrastim on cycle days 8±2 rather than cycle days 1 or 2 (with conventional chemotherapy) avoids high levels of exposure of the FOLR1 antibody conjugate simultaneously with pegfilgrastim. The half-life of FOLR1 antibody conjugates is longer than that of conventional small molecule chemotherapy drugs. Stimulation of granulopoiesis in the presence of high concentrations of potentially cytotoxic drugs (or radiation) may have a detrimental effect on granulocyte production (Viswanathan et al., 2014, Cancer 120(24):3870-83). Furthermore, FOLR1 antibody conjugate-associated neutropenia was found to occur primarily on cycle days 15-21, which is slower than that of small molecule cytotoxic agents.
[0016]
[0016] In some embodiments, the antibody conjugate binds to human folate receptor alpha. In some embodiments, the antibody conjugate also binds to a homolog of human folate receptor alpha. In some aspects, the antibody conjugate also binds to a homolog of cynomolgus monkey and / or mouse folate receptor alpha. In certain embodiments, the composition is a pharmaceutical composition. Any suitable pharmaceutical composition can be used. In certain embodiments, the pharmaceutical composition for the anti-FOLR1 antibody conjugate is a composition for intravenous (IV) administration.
[0017]
[0017] The methods, kits and compositions disclosed herein are useful for treating a disease or disorder. In certain embodiments, the disease or disorder is cancer. In certain embodiments, the cancer is endometrial cancer or ovarian cancer. In certain embodiments, conjugates and compositions for use in therapy are provided herein. In certain embodiments, conjugates and compositions for use in treating cancer are provided herein. [Brief description of the drawings]
[0018] Brief explanation of the figure [Figure 1]
[0018] Tumor reduction in patients after administration of the conjugates described herein at initial doses of 4.3 mg / kg or 5.2 mg / kg is demonstrated. [Diagram 2]
[0019] Objective patient response to administration of the conjugate described herein at an initial dose of 4.3 mg / kg or 5.2 mg / kg is presented. RECIST is Response Evaluation Criteria in Solid Tumors. CR is complete response, PR is partial response, PRu is unconfirmed partial response, SD is stable disease, and PD is progressive disease. [Diagram 3]
[0020] 1 presents the change in tumor diameter over time from treatment in patients receiving an initial dose of 4.3 mg / kg or 5.2 mg / kg of a conjugate described herein. [Figure 4]
[0021] The duration of treatment is presented in patients receiving an initial dose of 4.3 mg / kg or 5.2 mg / kg of a conjugate described herein. [Diagram 5]
[0022] The percentage of patients with positive histochemistry who received the conjugates described herein at an initial dose of 4.3 mg / kg or 5.2 mg / kg is presented. PR is partial response, PRu is unverified partial response, SD is stable disease, and PD is progressive disease. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] Detailed Description of the Preferred Embodiments 1.Definition
[0023] Unless otherwise defined, all technical terms, notations and other scientific terms used herein are intended to have the meanings commonly understood by those skilled in the art to which the present invention pertains. In some cases, terms having commonly understood meanings are defined herein for clarity and / or ease of reference, but the inclusion of such definitions herein should not necessarily be interpreted as representing a difference from what is commonly understood in the art. The techniques and procedures described or referenced herein are generally well understood by those skilled in the art and are commonly employed using conventional methodologies, such as the widely used molecular cloning methodologies described in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Where appropriate, procedures involving the use of commercially available kits and reagents are carried out according to manufacturer-specified protocols and conditions unless otherwise specified.
[0020]
[0024] Aspects and embodiments described herein as "comprising" are understood to include the embodiments "consisting of" and "consisting essentially of."
[0021]
[0025] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0022]
[0026] The term "about" denotes and encompasses the indicated value and a range above and below that value. In certain embodiments, the term "about" denotes the indicated value ±10%, ±5%, or ±1% of the indicated value. In certain embodiments, the term "about" denotes the indicated value ±1 standard deviation of that value.
[0023]
[0027] The term "combinations thereof" includes all possible combinations of the elements to which the term refers. For example, a sentence stating "If α2 is A, then α3 is not D; α5 is not S; or α6 is not S; or combinations thereof" includes the following combinations when α2 is A: (1) α3 is not D; (2) α5 is not S; (3) α6 is not S; (4) α3 is not D; α5 is not S; and α6 is not S; (5) α3 is not D and α5 is not S; (6) α3 is not D and α6 is not S; and (7) α5 is not S and α6 is not S.
[0024]
[0028] The terms "folate receptor alpha" and "folate receptor 1" are used interchangeably herein. Folate receptor alpha is also known by synonyms including, inter alia, FOLR1, FolRα, folate binding protein, FBP, adult folate binding protein, Folbp1, FR-α, FRα, KB cell FBP, and ovarian tumor associated antigen MOv18. Unless otherwise specified, the terms include all variants, isoforms, and species homologs of human folate receptor alpha expressed naturally by a cell or expressed by a cell transfected with a folate receptor alpha or FOLR1 gene. Folate receptor alpha proteins include, for example, human folate receptor alpha (SEQ ID NO: 1). In some embodiments, the folate receptor alpha protein comprises cynomolgus monkey folate receptor alpha (SEQ ID NO: 2). In some embodiments, the folate receptor alpha protein comprises mouse folate receptor alpha (SEQ ID NO: 3).
[0025]
[0029] As used herein, the term "angiogenesis inhibitor" refers to a substance that inhibits the formation of new blood vessels.
[0026]
[0030] The term "biologic" as used herein refers to a drug substance made or derived from a living organism, or made via recombinant DNA or controlled gene expression methodologies.
[0027]
[0031] The term "biosimilar" or "follow-on biologic" as used herein refers to a product that has similar structure and properties to an existing biologic product. Thus, the term "biosimilar" is generally used to describe a subsequent version (generally from a different source) of a previously approved and formally marketed "innovative biopharmaceutical product." Because biologics have a high degree of molecular complexity and are generally sensitive to changes in the manufacturing process (e.g., when different cell lines are used in their production), and because subsequent follow-on manufacturers generally do not have access to the originator's molecular clones, cell banks, know-how regarding the production process, and the active drug substance itself (only the innovator's commercialized drug product), a "biosimilar" may not be exactly the same as the innovator's drug product. However, biosimilars must demonstrate that they have no clinically meaningful differences from their reference products in terms of safety and efficacy. Thus, biosimilars are subsequent versions of known products that must be demonstrated to have no clinically meaningful differences from their reference products; as used herein, the term "biosimilar" includes all currently known and approved "biosimilars" as well as any "biosimilars" developed in the future.
[0028]
[0032] The term "immunoglobulin" refers to a class of structurally related proteins that generally contain two pairs of polypeptide chains: a pair of light (L) chains and a pair of heavy (H) chains. In an "intact immunoglobulin," all four of these chains are interconnected by disulfide bonds. The structure of immunoglobulins is well characterized. See, e.g., Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, PA. Briefly, each heavy chain typically contains a heavy chain variable region (V H ) and heavy chain constant region (C H The heavy chain constant region typically comprises H1 , C H2 and C H3Each light chain typically contains three domains, abbreviated as V L ) and a light chain constant region. The light chain constant region typically comprises L It contains one domain, abbreviated as .
[0029]
[0033] The term "antibody" refers to a type of immunoglobulin molecule and is used herein in its broadest sense. Antibodies include, inter alia, intact antibodies (e.g., intact immunoglobulins) and antibody fragments. An antibody comprises at least one antigen-binding domain. One example of an antigen-binding domain is the V H -V L The antigen-binding domain is formed by a dimer. "Folate receptor alpha antibody", "anti-folate receptor alpha antibody", "folate receptor alpha Ab", "folate receptor alpha specific antibody", "anti-folate receptor alpha Ab", "FOLR1 antibody", "FolRα antibody", "anti-FOLR1 antibody", "anti-FolRα antibody", "FOLR1 Ab", "FolRα Ab", "FOLR1 specific antibody", "FolRα specific antibody", "anti-FolRα Ab" or "anti-FOLR1 Ab" is an antibody that specifically binds to folate receptor alpha or FOLR1, as described herein. In some embodiments, the antibody binds to the extracellular domain of folate receptor alpha (FOLR1).
[0030]
[0034] V H and V L The regions can be further subdivided into hypervariable regions (HVRs; also called complementarity determining regions (CDRs)) interspersed with more conserved regions. The more conserved regions are called framework regions (FRs). H and V Lcontains three CDRs and four FRs, generally arranged in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (N-terminal to C-terminal). The CDRs are involved in antigen binding and affect the antigen specificity and binding affinity of the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, which is incorporated by reference in its entirety.
[0031]
[0035] The light chains of any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain.
[0032]
[0036] Heavy chains of vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also called α, δ, ε, γ, and μ, respectively. The IgG and IgA classes are further divided into subclasses based on sequence and functional differences. Humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.
[0033]
[0037] The amino acid sequence boundaries of the CDRs can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (the "Kabat" numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 (the "Chothia" numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (the "Contact" numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (the "IMGT" numbering scheme); and Honegge and Plueckthun, J. Mol. Biol., 2001, 309:657-70 (the "Aho" numbering scheme), each of which is incorporated by reference in its entirety.
[0034]
[0038] Table 1 provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes.
[0035] [Table 1]
[0036]
[0039] Unless otherwise stated, the numbering scheme used to identify a particular CDR herein is the Kabat / Chothia numbering scheme. When the residues encompassed by these two numbering schemes are different (e.g., CDR-H1 and / or CDR-H2), the numbering scheme is defined as Kabat or Chothia. For convenience, CDR-H3 is sometimes referred to as either Kabat or Chothia herein. However, this is not intended to imply sequence differences in their absence, and those skilled in the art can easily ascertain whether the sequences are the same or different by examining the sequences.
[0037]
[0040] CDRs can be assigned using antibody numbering software such as Abnum, as described in Abhinandan and Martin, Immunology, 2008, 45:3832-3839, available at www.bioinf.org.uk / abs / abnum / , and abYsis.org, Swindells et al. 2017, J. Mol. Biol. 429:356-364, each of which is incorporated by reference in its entirety.
[0038]
[0041] The "EU numbering scheme" is commonly used when referring to residues in antibody heavy chain constant regions (e.g., as reported in Kabat et al., supra). Unless otherwise specified, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.
[0039]
[0042] "Antibody fragment" includes a portion of an intact antibody, such as an antigen-binding region or a variable region of the intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab')2 fragments, Fab' fragments, scFv (sFv) fragments, and scFv-Fc fragments.
[0040]
[0043] An "Fv" fragment comprises a dimer of one heavy-chain and one light-chain variable domain in a non-covalent association.
[0041]
[0044] A "Fab" fragment contains the variable domain of the heavy chain and the variable domain of the light chain as well as the constant domain of the light chain and the first constant domain of the heavy chain (C H1 ). Fab fragments can be produced, for example, by recombinant methods or by papain digestion of a full-length antibody.
[0042]
[0045] "F(ab')2" fragments contain two Fab' fragments linked near the hinge region by disulfide bonds. F(ab')2 fragments can be produced, for example, by recombinant methods or by pepsin digestion of intact antibodies. F(ab') fragments can be dissociated, for example, by treatment with β-mercaptoethanol.
[0043]
[0046] "Single-chain Fv," or "sFv," or "scFv" antibody fragments contain the V H Domain and V L Includes domain. V H and V L are generally linked by a peptide linker. See Plueckthun A. (1994). In some embodiments, the linker is SEQ ID NO: 377. In some embodiments, the linker is SEQ ID NO: 378. Antibodies from Escherichia coli. In Rosenberg M. & Moore GP (Eds.), The Pharmacology of Monoclonal Antibodies vol. 113 (pp. 269-315). Springer-Verlag, New York, incorporated by reference in its entirety.
[0044]
[0047] An "scFv-Fc" fragment comprises an scFv attached to an Fc domain. For example, the Fc domain can be attached to the C-terminus of the scFv. The Fc domain is attached in the direction of the variable domains of the scFv (i.e., V H -V L Or V L -V H ) depending on V H Or V LAny suitable Fc domain known in the art or described herein may be used. Optionally, the Fc domain comprises an IgG1 Fc domain. In some embodiments, the IgG1 Fc domain comprises SEQ ID NO: 370, or a portion thereof. SEQ ID NO: 370 represents the C sequence of the human IgG1 constant region. H1 , C H2 and C H3 Provides an array of:
[0045]
[0048] The term "monoclonal antibody" refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies includes antibodies that bind to the same epitope substantially similarly, except for variants that may normally arise during the production of monoclonal antibodies. Such variants are generally present only in minor amounts. Monoclonal antibodies are typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones or other recombinant DNA clones. The selected antibody can be further modified, for example, to improve its affinity for the target ("affinity maturation"), humanize the antibody, improve its production in cell culture, and / or reduce its immunogenicity in a subject.
[0046]
[0049] The term "chimeric antibody" refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.
[0047]
[0050] "Humanized" forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from a non-human antibody. Humanized antibodies are generally human immunoglobulins (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken or non-human primate antibody, with the desired specificity, affinity or biological effect. In some cases, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody. Humanized antibodies may also contain residues that are not found in either the recipient antibody or the donor antibody. Such modifications may be made to further refine antibody function. For more details, see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is incorporated by reference in its entirety.
[0048]
[0051] A "human antibody" is one having an amino acid sequence that corresponds to the amino acid sequence of an antibody produced by a human or human cell, or that is derived from a non-human source that utilizes the human antibody repertoire or human antibody coding sequences (e.g., obtained from a human source or designed de novo). Human antibodies specifically exclude humanized antibodies.
[0049]
[0052] An "isolated antibody" is one that has been separated and / or recovered from a component of its natural environment. The components of the natural environment may include enzymes, hormones, and other proteinaceous or non-proteinaceous substances. In some embodiments, the isolated antibody is purified sufficiently to obtain at least 15 residues of N-terminal or internal amino acid sequence, for example, by use of a spinning cup sequencer. In some embodiments, the isolated antibody is purified to homogeneity by gel electrophoresis (e.g., SDS-PAGE) under reducing or non-reducing conditions with detection by Coomassie blue or silver staining. Since at least one component of the antibody's natural environment is absent, an isolated antibody includes the antibody in situ within a recombinant cell. In some aspects, the isolated antibody is prepared by at least one purification step.
[0050]
[0053] In some embodiments, the isolated antibody is purified to at least 80%, 85%, 90%, 95% or 99% by weight. In some embodiments, the isolated antibody is purified to at least 80%, 85%, 90%, 95% or 99% by volume. In some embodiments, the isolated antibody is provided in a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by volume. In some aspects, the isolated antibody is provided in a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by volume.
[0051]
[0054] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the intrinsic binding avidity that reflects a 1:1 interaction between binding pair members (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y is determined by the dissociation constant (K D) Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology, such as a Biacore® instrument. In some embodiments, affinity is determined at 25°C.
[0052]
[0055] With respect to antibody binding to a target molecule, the terms "specific binding," "specifically binds," "specific," "selectively binds," and "selective" to a particular antigen (e.g., a polypeptide target) or epitope on a particular antigen refer to binding that is measurably different from nonspecific or nonselective interactions. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule. Specific binding can also be determined by competition with a control molecule that mimics the antibody binding site on the target. Specific binding is then indicated if binding of the antibody to the target is competitively inhibited by the control molecule.
[0053]
[0056] "k d ”(seconds -1 The term k ) as used herein refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is known as k off Also called the value.
[0054]
[0057] "k a " " -1 × seconds -1 The term k ) as used herein refers to the binding rate constant for a particular antibody-antigen interaction. This value is known as k on Also called the value.
[0055]
[0058] "K D The term "(M)" as used herein refers to the dissociation equilibrium constant for a particular antibody-antigen interaction. D =k d / k a .
[0056]
[0059] "K A " " -1The term K ) as used herein refers to the binding equilibrium constant of a particular antibody-antigen interaction. A =k a / k d .
[0057]
[0060] An "affinity matured" antibody is one that has one or more modifications in one or more CDRs or FRs that result in an improvement in the affinity of the antibody for its antigen compared to the parent antibody without the modifications. In one embodiment, the affinity matured antibody has nanomolar or picomolar affinity for the target antigen. Affinity matured antibodies can be produced using a variety of methods known in the art. For example, Marks et al. (Bio / Technology, 1992, 10:779-783, which is incorporated by reference in its entirety) report on affinity matured antibodies. H and V L Affinity maturation by domain shuffling is described. Random mutagenesis of CDR and / or framework residues is described, for example, by Barbas et al. (Proc. Nat. Acad. Sci. USA, 1994, 91:3809-3813); Schier et al., Gene, 1995, 169:147-155; Yelton et al., J. Immunol., 1995, 155:1994-2004; Jackson et al., J. Immunol., 1995, 154:3310-33199; and Hawkins et al., J. Mol. Biol., 1992, 226:889-896, each of which is incorporated by reference in its entirety.
[0058]
[0061] The term "compete" or "cross-compete" as used herein in connection with two or more antibodies indicates that two or more antibodies compete for binding to an antigen (e.g., folate receptor alpha or FOLR1). In one exemplary assay, FOLR1 is coated on a plate and bound to a first antibody, and then a second, labeled antibody is added. The antibodies compete if the presence of the first antibody reduces the binding of the second antibody. In another exemplary assay, a first antibody is coated on a plate and bound to the antigen, and then a second antibody is added. The term "compete" also includes antibody combinations in which one antibody reduces the binding of another antibody, but no competition is observed when the antibodies are added in the reverse order. However, in some embodiments, the first and second antibodies inhibit binding to each other regardless of the order in which they are added. In some embodiments, one antibody reduces the binding of another antibody to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
[0059]
[0062] The term "epitope" refers to a portion of an antigen capable of specific binding to an antibody. Epitopes often consist of surface accessible amino acid residues and / or sugar side chains and may have specific three-dimensional structural characteristics as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished by the fact that the binding to the former but not the latter is lost in the presence of denaturing solvents. Epitopes may include amino acid residues that are directly involved in binding and other amino acid residues that are not directly involved in binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination, such as, for example, testing antibody binding to mutant forms of folate receptor alpha (FOLR1) with different point mutations.
[0060]
[0063] The percentage of "identity" between a polypeptide sequence and a reference sequence is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence after aligning the sequences and introducing gaps as necessary to achieve the maximum sequence identity percentage. Alignment to determine percent amino acid sequence identity can be achieved in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA or MUSCLE software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment over the entire length of the sequences being compared.
[0061]
[0064] "Conservative substitution" or "conservative amino acid substitution" refers to the replacement of an amino acid with a chemically or functionally similar amino acid. Conservative substitution tables providing similar amino acids are well known in the art. Polypeptide sequences having such substitutions are known as "conservatively modified variants." Such conservatively modified variants are in addition to, and do not exclude, polymorphic variants, interspecies homologs, and alleles. By way of example, the groups of amino acids provided in Tables 2-4 are, in some embodiments, considered conservative substitutions for one another.
[0062] [Table 2]
[0063] [Table 3]
[0064] [Table 4]
[0065] Additional conservative substitutions can be found, for example, in Creighton, Proteins: Structures and Molecular Properties 2nd ed. (1993) WH Freeman & Co., New York, NY. Antibodies created by making one or more conservative substitutions of amino acid residues of a parent antibody are referred to as "conservatively modified variants."
[0066]
[0066] The term "amino acid" refers to the 20 common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C); glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).
[0067]
[0067] Naturally encoded amino acids are proteinogenic amino acids known to those skilled in the art. They include the 20 common amino acids (alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine) and the less common pyrrolysine and selenocysteine. Naturally encoded amino acids include post-translational variants of the 22 natural amino acids, such as prenylated amino acids, isoprenylated amino acids, myrisoylated amino acids, palmitoylated amino acids, N-linked glycosylated amino acids, O-linked glycosylated amino acids, phosphorylated amino acids and acylated amino acids.
[0068]
[0068] The term "unnatural amino acid" refers to an amino acid that is not a proteinogenic amino acid or a post-translationally modified variant thereof. In particular, the term refers to an amino acid that is not one of the 20 common amino acids or to pyrrolysine or selenocysteine or a post-translationally modified variant thereof.
[0069]
[0069] The term "conjugate" or "antibody conjugate" refers to an antibody linked to one or more payload moieties. The antibody can be any antibody described herein. The payload can be any payload described herein. The antibody can be directly linked to the payload via a covalent bond or the antibody can be indirectly linked to the payload via a linker. Typically, the linker is covalently attached to the antibody and also covalently attached to the payload. The term "antibody drug conjugate" or "ADC" refers to a conjugate in which at least one payload is a therapeutic moiety such as a drug.
[0070]
[0070] The term "payload" refers to a molecular moiety that can be conjugated to an antibody. In certain embodiments, the payload is selected from the group consisting of a therapeutic moiety and a labeling moiety.
[0071] The term "linker" refers to a molecular moiety that can form at least two covalent bonds. Typically, a linker can form at least one covalent bond to an antibody and at least another covalent bond to a payload. In certain embodiments, a linker can form more than one covalent bond to an antibody. In certain embodiments, a linker can form more than one covalent bond to a payload or can form more than one covalent bond to a payload. After a linker forms a bond to an antibody or a payload or both, the remaining structure, i.e., the residue of the linker after one or more covalent bonds are formed, may still be referred to herein as a "linker". The term "linker precursor" refers to a linker that has one or more reactive groups that can form a covalent bond with an antibody or a payload or both. In some embodiments, the linker is a cleavable linker. For example, a cleavable linker may be a linker that is released by a biolabile functional group that may or may not be manipulated. In some embodiments, the linker is a non-cleavable linker. For example, a non-cleavable linker may be a linker that is released upon degradation of an antibody.
[0072]
[0072] The terms "pharmaceutical formulation" and "pharmaceutical composition" refer to a preparation that is in a form that allows the biological activity of the active ingredient to be effective and that does not contain additional ingredients that are unacceptably toxic to the individual to whom the formulation or composition will be administered. Such a formulation or composition may be sterile.
[0073]
[0073] As used herein, "excipient" includes a pharma- ceutically acceptable excipient, carrier, vehicle, or stabilizer that is non-toxic to cells or mammals exposed thereto at the dosages and concentrations used. In some embodiments, the physiologically acceptable excipient is an aqueous pH buffered solution.
[0074] "Treating" or "treatment" of any disease or disorder, in certain embodiments, refers to ameliorating a disease or disorder present in a subject. In another embodiment, "treating" or "treatment" includes improving at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, "treating" or "treatment" includes modulating the disease or disorder, either physically (e.g., stabilization of a discernible symptom) or physiologically (e.g., stabilization of a physical parameter), or both. In yet another embodiment, "treating" or "treatment" includes delaying or preventing the onset of a disease or disorder.
[0075]
[0075] As used herein, the term "therapeutically effective amount" or "effective amount" refers to an amount of an antibody or composition that is effective to treat a disease or disorder when administered to a subject. In some embodiments, a therapeutically effective amount or effective amount refers to an amount of an antibody or composition that is effective to prevent or ameliorate a disease or disease progression or result in amelioration of symptoms when administered to a subject.
[0076] As used herein, the term "inhibit proliferation" (e.g., with reference to cells, such as tumor cells) is intended to include any measurable decrease in cell proliferation (e.g., tumor cell proliferation) upon contact with a folate receptor alpha (FOLR1) antibody compared to proliferation of the same cells not contacted with the FOLR1 antibody. In some embodiments, proliferation may be inhibited by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99% or 100%. The decrease in cell proliferation may occur by a variety of mechanisms, including, but not limited to, antibody internalization, apoptosis, necrosis and / or effector function-mediated activity.
[0077]
[0077] As used herein, the term "subject" refers to a mammalian subject. Exemplary subjects include, but are not limited to, humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, birds, goats, and sheep. In certain embodiments, the subject is a human. In some embodiments, the subject has a disease that can be treated or diagnosed with the antibodies provided herein. In some embodiments, the disease is epithelial ovarian, fallopian tube, or primary peritoneal cancer. In some embodiments, the disease is gastric cancer, colorectal cancer, renal cell carcinoma, cervical cancer, non-small cell lung cancer, ovarian cancer, breast cancer, triple negative breast cancer, endometrial cancer, prostate cancer, and / or cancer of epithelial origin.
[0078]
[0078] As used herein, the term "cycle" refers to one period of administration in a dosing schedule. A cycle includes a day of administration and the days thereafter until the next administration. Exemplary cycles have lengths of 7 days, 10 days, 14 days, and 21 days.
[0079] In some of the chemical structures depicted herein, certain substituents, chemical groups, and atoms are represented by curved / wavy lines (e.g., [ka] ), which indicates the atom through which substituents, chemical groups, and atoms are attached. For example, [ka] In some structures, including but not limited to, the curved / wavy line indicates an atom in the backbone of the conjugate or linker-payload structure to which the depicted chemical entity is attached. [ka] In some structures, including but not limited to, the curved / wavy lines represent atoms in an antibody or antibody fragment as well as atoms in the backbone of a conjugate or linker-payload structure to which the depicted chemical entity is attached.
[0080] The term "site-specific" refers to the modification of a polypeptide at a predetermined sequence location of the polypeptide. The modification is at a single, predictable residue of the polypeptide with little or no variation. In certain embodiments, a modified amino acid is introduced, for example, recombinantly or synthetically, at a sequence location. Similarly, a moiety can be "site-specifically" linked to a residue at a particular sequence location in a polypeptide. In certain embodiments, a polypeptide can contain two or more site-specific modifications.
[0081] 1. Administration
[0081] Provided herein is a method of treating cancer in a patient in need thereof by administering an anti-FOLR1 antibody drug conjugate according to a dosing schedule. The patient may be any patient that a professional considers suitable for treatment. In certain embodiments, the patient has cancer. In certain embodiments, the patient has endometrial cancer. In certain embodiments, the patient has ovarian cancer. In certain embodiments, the subject has previously been treated for cancer. In certain embodiments, the subject has not previously been treated for cancer.
[0082]
[0082] The anti-FOLR1 antibody conjugate or composition thereof is suitably administered to the patient over a course of treatment. In certain embodiments, the anti-FOLR1 antibody conjugate is administered in two different doses. In certain embodiments, the anti-FOLR1 antibody conjugate described herein is administered to the individual in a fixed dose based on the individual's body weight (e.g., mg / kg).
[0083]
[0083] In certain embodiments, the anti-FOLR1 antibody conjugate is administered 1-3 times at a first dose, and then at least 1-3 times at a second dose. In certain embodiments, the second dose is lower than the first dose. In certain embodiments, the first dose is administered for one cycle. In certain embodiments, the first dose is administered for two cycles. In certain embodiments, the first dose is administered for three cycles. In certain embodiments, the second dose is administered for at least one cycle. In certain embodiments, the second dose is administered for at least two cycles. In certain embodiments, the second dose is administered for at least three cycles. In certain embodiments, the second dose is administered for the remainder of the treatment. In certain embodiments, each cycle is one week after the previous cycle.
[0084]
[0084] Each dose may be administered according to a suitable schedule, for example, once, twice, three or four times per week. In certain embodiments, each dose is administered about once every 3, 4 or 5 weeks. In certain embodiments, each dose is administered about once every 3 weeks. In certain embodiments, each dose is administered about once every 4 weeks. In certain embodiments, each dose is administered about once every 5 weeks. In certain embodiments, each dose is administered daily. In certain embodiments, each dose is separated from the previous dose by a cycle length. In certain embodiments, the cycle length is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 10 days or 2 weeks, 3 weeks, 4 weeks or more. In certain embodiments, the cycle length is 21 days. The cycle length may be 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 days. In certain embodiments, the clinician or practitioner will adjust the cycle length. In certain embodiments, the clinician or practitioner will switch the first dose to the second dose as described herein. In addition, it should be noted that the clinician or practitioner will know how and when to interrupt, adjust or terminate the treatment in relation to the subject's response. For example, the clinician or practitioner may further adjust the dose level in relation to the side effects of the subject's treatment or the underlying disease that the subject is being treated for.
[0085]
[0085] In certain embodiments, the first dose is about 5.2 mg / kg. In certain embodiments, the first dose is 5.2 mg / kg. In certain embodiments, the second dose is about 4.3 mg / kg. In certain embodiments, the second dose is 4.3 mg / kg. In certain embodiments, the first dose is about 5.2 mg / kg and the second dose is about 4.3 mg / kg. In certain embodiments, the first dose is 5.2 mg / kg and the second dose is 4.3 mg / kg. In certain embodiments, the administration is by intravenous (IV) administration.
[0086]
[0086] In certain embodiments, the first dose is about 4.3 mg / kg. In certain embodiments, the first dose is 4.3 mg / kg. In certain embodiments, the first dose is about 4.3 mg / kg and the second dose is about 3.5 mg / kg. In certain embodiments, the first dose is 4.3 mg / kg and the second dose is 3.5 mg / kg.
[0087]
[0087] In certain embodiments, the second dose is about 4.3 mg / kg. In certain embodiments, the second dose is 4.3 mg / kg. In certain embodiments, the second dose is about 3.5 mg / kg. In certain embodiments, the second dose is 3.5 mg / kg. In certain embodiments, the second dose is about 2.9 mg / kg. In certain embodiments, the second dose is 2.9 mg / kg.
[0088] In a particular embodiment, the first dose is about 5.2 mg / kg; the second dose is administered after the first dose, the amount of the second dose is less than the amount of the first dose, and the first and second doses are administered at least about 3 weeks apart. In a particular embodiment, the second dose is about 4.3 mg / kg or less; the second dose is administered after the first dose, the amount of the first dose is greater than the amount of the second dose, and the first dose is administered once every 3 weeks or more for 1 to 6 cycles. In a particular embodiment, the second dose is administered after the first dose, the amount of the first dose is the same as or greater than the amount of the second dose, a tumor tissue sample from the subject has a tumor proportion score (TPS) of about 25% or more, and the subject has a tumor reduction of at least 30% by volume 3 weeks after administration of the first dose.
[0089]
[0089] In certain embodiments, the first dose is about 5.2 mg / kg. In certain embodiments, the second dose is about 4.3 mg / kg or less. In certain embodiments, the second dose is about 4.3 mg / kg. In certain embodiments, the first dose is about 5.2 mg / kg and the second dose is about 4.3 mg / kg.
[0090]
[0090] In certain embodiments, the method further comprises administering a third dose of the FOLR1 antibody conjugate. In certain embodiments, the amount of the third dose is less than the amount of the second dose. In certain embodiments, the amount of the third dose is about 3.5 mg / kg or less. In certain embodiments, the amount of the third dose is about 3.5 mg / kg. In certain embodiments, the amount of the third dose is 3.5 mg / kg. In certain embodiments, the amount of the third dose is about 2.9 mg / kg. In certain embodiments, the amount of the third dose is 2.9 mg / kg. In certain embodiments, the first dose is about 5.2 mg / kg, the second dose is about 4.3 mg / kg, and the third dose is about 3.5 mg / kg. In a particular embodiment, the first dose is about 4.3 mg / kg, the second dose is about 3.5 mg / kg, and the third dose is about 2.9 mg / kg.
[0091] In certain embodiments, a dose of the antibody conjugate or composition provided herein may be administered to achieve a steady state concentration of the antibody in the blood or serum of the subject. The steady state concentration may be determined by measuring according to techniques available to those skilled in the art, or may be based on the subject's physical characteristics, such as height, weight, and age.
[0092] In certain embodiments, therapy continues until the patient reaches remission or partial remission. In certain embodiments, therapy continues until the clinician or treating physician decides to stop. In certain embodiments, therapy continues for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 weeks or more.
[0093]
[0093] In certain embodiments, the first dose is administered once about every 3 weeks or more for 1 to 5 cycles. In certain embodiments, the first dose is administered once every 3 weeks or more for 1 to 5 cycles. For example, the first dose can be administered once about every 3, 4, or 5 weeks for 1, 2, 3, 4, or 5 cycles. In certain embodiments, the first dose is administered for 1 to 3 cycles. In certain embodiments, the first dose is administered for 2 to 4 cycles. In certain embodiments, the second dose is administered at least about 3 weeks after the first dose is administered. In certain embodiments, the second dose is administered at least about 6 weeks after the first dose is administered. In certain embodiments, the second dose is administered at least about 6 weeks after the first dose is administered. In certain embodiments, the second dose is administered once every 3 weeks. In certain embodiments, the second dose is administered once every 3 weeks for at least about 3 weeks. In certain embodiments, the second dose is administered once every 3 weeks for at least about 2 months. In certain embodiments, the second dose is administered once every 3 weeks for at least about 3 months. In certain embodiments, the second dose is administered once every 3 weeks for at least about 4 months. In certain embodiments, the second dose is administered once every 3 weeks for the remainder of the treatment. In certain embodiments, the first dose and the second dose are administered at least about 3 weeks apart. For example, the first dose and the second dose can be administered about 3, 4, 5 or 6 weeks apart.
[0094] 2. Conjugates
[0094] In the method, the anti-FOLR1 antibody conjugate can be any anti-FOLR1 antibody conjugate provided herein. The conjugate comprises an antibody against FOLR1 covalently linked directly to a payload or indirectly via a linker. In certain embodiments, the antibody is linked to one payload. In further embodiments, the antibody is linked to two or more payloads. In certain embodiments, the antibody is linked to two, three, four, five, six, seven, eight or more payloads. In certain embodiments, the anti-FOLR1 antibody conjugate is an anti-FOLR1 antibody conjugate described in U.S. Pat. No. 10,596,270, the contents of which are incorporated herein by reference.
[0095] In certain embodiments, the anti-FOLR1 antibody conjugate is according to the formula of conjugate P described herein, and the antibody is 1848-H01 conjugated via p-azidomethylphenylalanine residues at heavy chain positions Y180 and F404. In certain embodiments, the antibody of the anti-FOLR1 antibody conjugate comprises the three heavy chain CDRs of SEQ ID NO: 362 in the heavy chain and the three light chain CDRs of SEQ ID NO: 367 in the light chain. In certain embodiments, the antibody of the anti-FOLR1 antibody conjugate comprises the three heavy chain CDRs of SEQ ID NO: 58, 176, and 294, and the three light chain CDRs of SEQ ID NO: 367 in the light chain. The antibody of the anti-FOLR1 antibody conjugate comprises the three heavy chain CDRs of SEQ ID NO: 117, 235, and 294, and the three light chain CDRs of SEQ ID NO: 367 in the light chain. In certain embodiments, the antibody of the anti-FOLR1 antibody conjugate comprises a heavy chain VH region of SEQ ID NO: 362 and a light chain VL region of SEQ ID NO: 367. In certain embodiments, the antibody of the anti-FOLR1 antibody conjugate comprises a heavy chain SEQ ID NO: 362 and a light chain VL region of SEQ ID NO: 367. In each of these embodiments, the antibody may comprise a Y180 and F404 mutation to p-azidomethylphenylalanine.
[0096]
[0096] The payload can be any payload deemed useful by experts. In certain embodiments, the payload is a therapeutic moiety. In certain embodiments, the payload is a diagnostic moiety, such as, for example, a label. Useful payloads are described in the following sections and examples.
[0097]
[0097] The linker can be any linker capable of forming at least one bond to the antibody and at least one bond to the payload. Useful linkers are described in the following sections and examples.
[0098] In the conjugates provided herein, the antibody can be any antibody having binding specificity for folate receptor alpha (FOLR1 or FolRα). FOLR1 can be from any species. In certain embodiments, FOLR1 is vertebrate FOLR1. In certain embodiments, FOLR1 is mammalian FOLR1. In certain embodiments, FOLR1 is human FOLR1. In certain embodiments, FOLR1 is mouse FOLR1. In certain embodiments, FOLR1 is cynomolgus monkey FOLR1.
[0099] In certain embodiments, an antibody against folate receptor alpha (FOLR1 or FolRα) competes for binding with an antibody described herein. In certain embodiments, an antibody against FOLR1 binds to the same epitope as an antibody described herein.
[0100]
[0100] An antibody is typically a protein comprising multiple polypeptide chains. In certain embodiments, an antibody is a heterotetramer comprising two identical light (L) chains and two identical heavy (H) chains. Each light chain may be linked to a heavy chain by one covalent disulfide bond. Each heavy chain may be linked to the other heavy chain by one or more covalent disulfide bonds. Each heavy and light chain may also have one or more intrachain disulfide bonds. As known to those skilled in the art, each heavy chain typically comprises a variable domain (V H) followed by several constant domains. Each light chain typically contains a variable domain (V L ) and constant domains. As is known to those skilled in the art, antibodies typically have a selective affinity for their target molecules, i.e., antigens.
[0101]
[0101] The antibodies provided herein may have any antibody form known to those skilled in the art. They may be full-length or fragments. Exemplary full-length antibodies include IgA, IgA1, IgA2, IgD, IgE, IgG, IgG1, IgG2, IgG3, IgG4, IgM, etc. Exemplary fragments include Fv, Fab, Fc, scFv, scFv-Fc, etc.
[0102] In certain embodiments, the antibody of the conjugate comprises one, two, three, four, five or six of the CDR sequences described herein. In certain embodiments, the antibody of the conjugate comprises a heavy chain variable domain (V H In certain embodiments, the antibody of the conjugate comprises a light chain variable domain (V L In certain embodiments, the antibody of the conjugate comprises a heavy chain variable domain (V H ) and a light chain variable domain (V L In certain embodiments, the antibody of the conjugate comprises a heavy chain variable domain and a light chain variable domain pair (V H -V L (vs.)
[0103]
[0103] In certain embodiments, the antibody of the conjugate comprises any of the amino acid sequences of the antibodies described above. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 10 amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 9 amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 8 amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 7 amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 6 amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 5 amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 4 amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 3 amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 2 amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 1 conservative amino acid substitution. In some embodiments, the amino acid substitution is a conservative amino acid substitution. For example, in certain embodiments, the antibody comprises any of the above amino acid sequences with up to 10 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 9 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 8 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 7 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 6 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 5 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 4 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to 3 conservative amino acid substitutions.In certain embodiments, the antibody comprises any of the above amino acid sequences with up to two conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the above amino acid sequences with up to one conservative amino acid substitution.
[0104] In certain embodiments, antibody conjugates may be formed from antibodies that contain one or more reactive groups. In certain embodiments, antibody conjugates may be formed from antibodies that contain all naturally encoded amino acids. Those skilled in the art will recognize that some naturally encoded amino acids contain reactive groups that can be conjugated to a payload or linker. These reactive groups include cysteine side chains, lysine side chains, and amino terminal groups. In these embodiments, the antibody conjugates may include a payload or linker linked to a residue of an antibody reactive group. In these embodiments, the payload precursor or linker precursor includes a reactive group that can form a bond with the antibody reactive group. Exemplary reactive groups include maleimide groups, activated carbonates (including but not limited to p-nitrophenyl esters), activated esters (including but not limited to N-hydroxysuccinimide, p-nitrophenyl esters, and aldehydes). Particularly useful reactive groups include maleimides and succinimides, such as, for example, N-hydroxysuccinimide for forming bonds to cysteine and lysine side chains. Further reactive groups are described in the following sections and examples.
[0105] In further embodiments, the antibody comprises one or more modified amino acids with reactive groups as described herein. Typically, the modified amino acids are not naturally encoded amino acids. These modified amino acids may comprise reactive groups useful for forming covalent bonds to linker precursors or payload precursors. One skilled in the art may use the reactive groups to link a polypeptide to any molecular entity capable of forming a covalent bond to a modified amino acid. Thus, conjugates are provided herein that comprise an antibody comprising a modified amino acid residue linked directly or indirectly to a payload via a linker. Exemplary modified amino acids are described in the following sections. Generally, the modified amino acid has a reactive group capable of forming a bond to a linker or payload with a complementary reactive group.
[0106]
[0106] The unnatural amino acids are placed at selected positions in the polypeptide chain of the antibody. These locations are identified as providing optimal sites for substitution with unnatural amino acids. Each site can bear an unnatural amino acid with an optimal structure, function and / or process for generating the antibody.
[0107]
[0107] In certain embodiments, the site-specific locations for substitutions provide for stable antibodies. Stability can be measured by any technique apparent to one of skill in the art.
[0108] In certain embodiments, the site-specific locations for substitutions provide antibodies with optimal functional properties. For example, an antibody may exhibit little or no loss of binding affinity to its target antigen compared to an antibody that does not contain the site-specific unnatural amino acid. In certain embodiments, an antibody may exhibit enhanced binding compared to an antibody that does not contain the site-specific unnatural amino acid.
[0109]
[0109] In certain embodiments, the site-specific locations for substitution provide antibodies that can be advantageously generated. For example, in certain embodiments, the antibodies exhibit advantageous properties in the methods of synthesis thereof discussed below. In certain embodiments, the antibodies may exhibit little or no loss in yield in production compared to antibodies that do not include the site-specific unnatural amino acid. In certain embodiments, the antibodies may exhibit enhanced yield in production compared to antibodies that do not include the site-specific unnatural amino acid. In certain embodiments, the antibodies may exhibit little or no loss in tRNA inhibition compared to antibodies that do not include the site-specific unnatural amino acid. In certain embodiments, the antibodies may exhibit enhanced tRNA inhibition in production compared to antibodies that do not include the site-specific unnatural amino acid.
[0110]
[0110] In certain embodiments, the site-specific locations for substitution provide antibodies with advantageous solubility. In certain embodiments, the antibodies may exhibit little or no loss in solubility compared to antibodies that do not include the site-specific unnatural amino acid. In certain embodiments, the antibodies may exhibit enhanced solubility compared to antibodies that do not include the site-specific unnatural amino acid.
[0111]
[0111] In certain embodiments, the site-specific locations for substitutions provide antibodies with advantageous expression. In certain embodiments, the antibodies may exhibit little or no loss of expression compared to antibodies that do not include the site-specific unnatural amino acid. In certain embodiments, the antibodies may exhibit enhanced expression compared to antibodies that do not include the site-specific unnatural amino acid.
[0112]
[0112] In certain embodiments, the site-specific locations for substitutions provide antibodies with favored folding. In certain embodiments, the antibodies may exhibit little or no loss of proper folding compared to antibodies that do not include the site-specific unnatural amino acid. In certain embodiments, the antibodies may exhibit enhanced folding compared to antibodies that do not include the site-specific unnatural amino acid.
[0113] In certain embodiments, the site-specific locations for substitution provide the antibody with favorable conjugation capabilities. As described below, some unnatural amino acids have side chains or functional groups that facilitate conjugation of the antibody to a second agent, either directly or via a linker. In certain embodiments, the antibody may exhibit enhanced conjugation efficiency compared to antibodies that do not contain the same or other unnatural amino acids at other positions. In certain embodiments, the antibody may exhibit enhanced conjugation yield compared to antibodies that do not contain the same or other unnatural amino acids at other positions. In certain embodiments, the antibody may exhibit enhanced conjugation specificity compared to antibodies that do not contain the same or other unnatural amino acids at other positions.
[0114]
[0114] The one or more unnatural amino acids are placed at selected site-specific positions in at least one polypeptide chain of the antibody. The polypeptide chain can be any polypeptide chain of the antibody, including without limitation, either the light chain or the heavy chain. The site-specific positions can be in any domain of the antibody, including any variable domain and any constant domain.
[0115]
[0115] In certain embodiments, the antibodies provided herein comprise one unnatural amino acid at the site-specific position. In certain embodiments, the antibodies provided herein comprise two unnatural amino acids at the site-specific position. In certain embodiments, the antibodies provided herein comprise three unnatural amino acids at the site-specific position. In certain embodiments, the antibodies provided herein comprise more than three unnatural amino acids at the site-specific position.
[0116] In certain embodiments, the antibodies provided herein comprise one or more unnatural amino acids or post-translationally modified variants thereof at heavy or light chain residues HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, or HC-S70, respectively, according to the Kabat or Chothia or EU numbering scheme. In these nomenclature, HC denotes a heavy chain residue and LC denotes a light chain residue.
[0117] In certain embodiments, the antibody is site-specifically linked to at least one payload. In certain embodiments, the antibody comprises one or more unnatural amino acids at a site selected from the group consisting of HC F404, HC-K121, HC-Y180, HC-F241, HC-221, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, or HC-S70 according to the Kabat, Chothia, or EU numbering scheme. In certain embodiments, the antibody comprises one or more unnatural amino acids at a site selected from the group consisting of HC F404, HC-Y180, and LC-K42 according to the Kabat, Chothia, or EU numbering scheme. In certain embodiments, the antibody comprises an unnatural amino acid at position HC-F404. In certain embodiments, the antibody comprises an unnatural amino acid at position HC-F404. In certain embodiments, the antibody comprises an unnatural amino acid at positions HC-F404 and HC-Y180. In certain embodiments, the residue of the one or more unnatural amino acids is linked to the payload moiety via a hydrolytically stable linker. In certain embodiments, the residue of the one or more unnatural amino acids is linked to the payload moiety via a cleavable linker.
[0118] In certain embodiments, the one or more unnatural amino acids are selected from the group consisting of p-acetyl-L-phenylalanine, O-methyl-L-tyrosine, -3-(2-naphthyl)alanine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, tri-O-acetyl-GlcNAcP-serine, L-Dopa, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-azido-methyl-L-phenylalanine, compound 56, p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, L-phosphoserine, phosphonoserine, phosphonotyrosine, p-iodo-phenylalanine, p-bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, and p-propargyloxy-phenylalanine. In certain embodiments, the unnatural amino acid residue is a residue of compound (30) or compound (56).
[0119]
[0119] In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of a non-natural amino acid according to formula (30) below at heavy chain position 404 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of a non-natural amino acid according to formula (30) below at heavy chain position 180 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of a non-natural amino acid according to formula (30) below at heavy chain position 241 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of an unnatural amino acid according to formula (30) below at heavy chain position 222 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of an unnatural amino acid according to formula (30) below at light chain position 7 according to the Kabat or Chothia numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of an unnatural amino acid according to formula (30) below at light chain position 42 according to the Kabat or Chothia numbering system. In certain embodiments, PAY is selected from the group consisting of maytansine, hemiasterin, amanitin, monomethylauristatin F (MMAF) and monomethylauristatin E (MMAE). In certain embodiments, PAY is maytansine. In certain embodiments, PAY is hemiasterlin. In certain embodiments, PAY is amanitin. In certain embodiments, PAY is MMAF. In certain embodiments, PAY is MMAE.
change
[0120]
[0120] In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of a non-natural amino acid according to formula (56) below at heavy chain position 404 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of a non-natural amino acid according to formula (56) below at heavy chain position 180 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of a non-natural amino acid according to formula (56) below at heavy chain position 241 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of an unnatural amino acid according to formula (56) below at heavy chain position 222 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of an unnatural amino acid according to formula (56) below at light chain position 7 according to the Kabat or Chothia numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents a residue of an unnatural amino acid according to formula (56) below at light chain position 42 according to the Kabat or Chothia numbering system. In certain embodiments, PAY is selected from the group consisting of maytansine, hemiasterlin, amanitin, MMAF, and MMAE. In certain embodiments, PAY is maytansine. In certain embodiments, PAY is hemiasterlin. In certain embodiments, PAY is amanitin. In certain embodiments, PAY is MMAF. In certain embodiments, PAY is MMAE. [ka]
[0121]
[0121] In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents the non-natural amino acid residue of paraazido-L-phenylalanine. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents the non-natural amino acid residue of paraazido-L-phenylalanine at heavy chain position 404 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents the non-natural amino acid residue of paraazido-L-phenylalanine at heavy chain position 180 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents the unnatural amino acid residue paraazido-L-phenylalanine at heavy chain position 241 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents the unnatural amino acid residue paraazido-L-phenylalanine at heavy chain position 222 according to the EU numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of formulas 101a-104b, where COMP represents the unnatural amino acid residue paraazido-L-phenylalanine at light chain position 7 according to the Kabat or Chothia numbering system. In certain embodiments, provided herein is an anti-FOLR1 conjugate according to any of Formulas 101a-104b, where COMP represents the unnatural amino acid residue paraazido-L-phenylalanine at light chain position 42 according to the Kabat or Chothia numbering system. In certain embodiments, PAY is selected from the group consisting of maytansine, hemiasterlin, amanitin, MMAF, and MMAE. In certain embodiments, PAY is maytansine. In certain embodiments, PAY is hemiasterlin. In certain embodiments, PAY is amanitin. In certain embodiments, PAY is MMAF. In certain embodiments, PAY is MMAE.
[0122] In certain embodiments, at least one payload moiety is selected from the group consisting of maytansine, hemiasterlin, amanitin, and auristatin. In certain embodiments, at least one payload moiety is selected from the group consisting of DM1, hemiasterlin, amanitin, MMAF, and MMAE. In certain embodiments, at least one payload moiety is a hemiasterlin derivative. In certain embodiments, at least one payload moiety is [ka] where Ar is aryl or heteroaryl, L is a linker, and the wavy line indicates the bond to the antibody. In certain embodiments, at least one payload moiety is [ka] where L is a linker and the wavy line indicates the bond to the antibody. It is.
[0123]
[0123] In some embodiments, the present specification provides an anti-FOLR1 conjugate comprising a modified hemiasterlin and a linker, as described in WO 2016 / 123582. For example, the conjugate may have a structure comprising any of formulas 1000-1000b, 1001-1001b, 1002-1002b and I-XIXb-2, 101-111b or 1-8b, as described in WO 2016 / 2016 / 123582. Examples of conjugates comprising modified hemiasterlin and a linker are provided below.
[0124] In some embodiments, the conjugate M: [ka] (wherein n is an integer of 1 to 6). Provided herein is an anti-FOLR1 conjugate having the structure: In some embodiments, n is an integer from 1 to 4. In some embodiments, n is 2. For example, in some embodiments, the anti-FOLR1 conjugate has the structure: [ka] In some embodiments, n is 4. For example, in some embodiments, the anti-FOLR1 conjugate has the structure: [ka] has.
[0125] In some embodiments, the conjugate P: [ka] (wherein n is an integer of 1 to 6). Provided herein is an anti-FOLR1 conjugate having the structure: In some embodiments, n is an integer from 1 to 4. In some embodiments, n is 2. For example, in some embodiments, the anti-FOLR1 conjugate has the structure: [ka] In some embodiments, n is 4. For example, in some embodiments, the anti-FOLR1 conjugate has the structure: [ka] has.
[0126] In some embodiments, the conjugate Q: [ka] (wherein n is an integer of 1 to 6). Provided herein is an anti-FOLR1 conjugate having the structure: In some embodiments, n is an integer from 1 to 4. In some embodiments, n is 2. For example, in some embodiments, the anti-FOLR1 conjugate has the structure: [ka] In some embodiments, n is 4. For example, in some embodiments, the anti-FOLR1 conjugate has the structure: [ka] has.
[0127] In any of the above aspects where the anti-FOLR1 conjugate has a structure according to conjugate M, conjugate P or conjugate Q, the bracketed structure may be covalently attached to one or more unnatural amino acids of the antibody, the one or more unnatural amino acids being located at a site selected from the group consisting of HC-F404, HC-Y180 and LC-K42 according to Kabat or EU numbering scheme of Kabat. In some embodiments, the bracketed structure is covalently attached to one or more unnatural amino acids at site HC-F404 of the antibody. In some embodiments, the bracketed structure is covalently attached to one or more unnatural amino acids at site HC-Y180 of the antibody. In some embodiments, the bracketed structure is covalently attached to one or more unnatural amino acids at site LC-K42 of the antibody. In some embodiments, the bracketed structure is covalently attached to one or more unnatural amino acids at sites HC-F404 and HC-Y180 of the antibody. In some embodiments, at least one bracketed structure is covalently bound to an unnatural amino acid at site HC-F404 of the antibody and at least one bracketed structure is covalently bound to an unnatural amino acid at site HC-Y180 of the antibody. In some embodiments, the bracketed structure is covalently bound to one or more unnatural amino acids at sites HC-Y180 and LC-K42 of the antibody. In some embodiments, at least one bracketed structure is covalently bound to an unnatural amino acid at site HC-Y180 of the antibody and at least one bracketed structure is covalently bound to an unnatural amino acid at site LC-K32 of the antibody.
[0128] 5. Antibody specificity
[0128] The conjugate comprises an antibody that selectively binds to human folate receptor alpha. In some embodiments, the antibody selectively binds to the extracellular domain of human folate receptor alpha (human FOLR1).
[0129] In some embodiments, the antibody binds to a homolog of human FOLR1. In some aspects, the antibody binds to a homolog of human FOLR1 from a species selected from monkey, mouse, dog, cat, rat, cow, horse, goat, and sheep. In some aspects, the homolog is a cynomolgus monkey homolog. In some aspects, the homolog is a mouse or a mouse analog.
[0130] In some embodiments, the antibody comprises at least one CDR sequence defined by the consensus sequence provided in this disclosure. In some embodiments, the antibody comprises at least one CDR sequence defined by the exemplary CDR, V H Or V L In some embodiments, the variant is a variant having conservative amino acid substitutions.
[0131] In some embodiments, an antibody has one or more CDRs with a particular length in terms of number of amino acid residues. In some embodiments, the Chothia CDR-H1 of the antibody is 6, 7 or 8 residues long. In some embodiments, the Kabat CDR-H1 of the antibody is 4, 5 or 6 residues long. In some embodiments, the Chothia CDR-H2 of the antibody is 5, 6 or 7 residues long. In some embodiments, the Kabat CDR-H2 of the antibody is 16, 17 or 18 residues long. In some embodiments, the Kabat / Chothia CDR-H3 of the antibody is 13, 14, 15, 16 or 17 residues long.
[0132] In some embodiments, the Kabat / Chothia CDR-L1 of the antibody is 11, 12, 13, 14, 15, 16, 17, or 18 residues in length. In some embodiments, the Kabat / Chothia CDR-L2 of the antibody is 6, 7, or 8 residues in length. In some embodiments, the Kabat / Chothia CDR-L3 of the antibody is 8, 9, or 10 residues in length.
[0133]
[0133] In some embodiments, the antibody comprises a light chain. In some aspects, the light chain is a κ light chain. In some aspects, the light chain is a λ light chain.
[0134] In some embodiments, the antibody comprises a heavy chain. In some aspects, the heavy chain is IgA. In some aspects, the heavy chain is IgD. In some aspects, the heavy chain is IgE. In some aspects, the heavy chain is IgG. In some aspects, the heavy chain is IgM. In some aspects, the heavy chain is IgG1. In some aspects, the heavy chain is IgG2. In some aspects, the heavy chain is IgG3. In some aspects, the heavy chain is IgG4. In some aspects, the heavy chain is IgA1. In some aspects, the heavy chain is IgA2.
[0135] In some embodiments, the antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab')2 fragment. In some aspects, the antibody fragment is a Fab' fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment.
[0136] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.
[0137]
[0137] In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody.
[0138] In some embodiments, the antibody is an affinity matured antibody. In some aspects, the antibody is an affinity matured antibody derived from the exemplary sequences provided in this disclosure.
[0139]
[0139] The antibodies provided herein may be useful in the treatment of various diseases and conditions, including cancer. In some embodiments, the antibodies provided herein may be useful in the treatment of solid tumor cancer. For example, the antibodies provided herein may be useful in the treatment of colorectal cancer.
[0140] In certain embodiments, the antibody comprises a V H Regions and V L In certain embodiments, the V H The region is selected from SEQ ID NOs: 308 to 366. L The region is selected from SEQ ID NOs: 367-369. H The region is according to SEQ ID NO: 362, L The region is according to SEQ ID NO: 367. CDR sequences can be identified by routine techniques well known to those skilled in the art. In certain embodiments, the CDRs are identified according to Kabat numbering. In certain embodiments, the CDRs are identified according to Chothia numbering. In certain embodiments, the CDRs are identified according to Martin numbering. In certain embodiments, the CDRs are identified according to contact numbering. In certain embodiments, the CDRs are identified according to AHo numbering. In certain embodiments, the CDRs are identified according to IMGT numbering. Tools for identifying CDR sequences are available (e.g., abYsis or abnum, as above).
[0141] 5.1 CDR-H3 sequence In some embodiments, the antibody is an exemplary antibody or V H In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of the CDR-H3 sequence of SEQ ID NOs: 308-366. H The sequence is the CDR-H3 sequence of the sequence.
[0142]
[0142] In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 240-298. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 240. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 241. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 242. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 243. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 244. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 245. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 246. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:247. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:248. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:249. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:250. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:251. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:252. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:253. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:254. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:255.In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 256. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 257. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 258. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 259. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 260. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 261. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 262. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 263. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 264. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 265. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 266. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 267. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 268. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 269. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 270. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 271. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:272.In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:273. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:274. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:275. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:276. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:277. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:278. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:279. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:280. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:281. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:282. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:283. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:284. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:285. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:286. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:287. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:288. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:289.In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:290. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:291. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:292. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:293. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:294. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:295. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:296. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:297. In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:298.
[0143] In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-H3 sequence provided in this disclosure. In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-H3 sequences provided in this disclosure. In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-H3 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0144] 5.2 Exemplary CDR-Containing V H array In some embodiments, the antibody comprises one or more CDR-H sequences that comprise, consist of, or consist essentially of one or more exemplary CDR-H sequences provided in this disclosure and variants thereof. H In some embodiments, the CDR-H sequence comprises a V sequence selected from SEQ ID NOs: 308-366. H The CDR-H sequence may comprise, consist of or consist essentially of one or more of the CDR-H sequences provided in the sequence.
[0145] 5.2.1. V with Exemplary Kabat CDRs H array In some embodiments, the antibody comprises a V sequence comprising one or more Kabat CDR-H sequences that comprise, consist of, or consist essentially of one or more exemplary Kabat CDR-H sequences provided in this disclosure and variants thereof. H Contains arrays.
[0146] Kabat CDR-H3 In some embodiments, the antibody comprises a V H The CDR-H3 sequence is an exemplary antibody or V H In some embodiments, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of the Kabat CDR-H3 sequence of SEQ ID NOs: 308-366. H The sequence is the Kabat CDR-H3 sequence.
[0147] In some embodiments, the antibody comprises a V domain comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 240-298. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:240. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:241. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:242. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:243. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:244. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:245. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:246. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:247. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:248. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:249. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:250. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:251. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:252. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:253. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:254. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:255. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:256. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:257. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:258. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:259. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:260. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:261. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:262. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:263. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:264. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:265. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:266. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:267. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:268. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:269. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:270. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:271. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:272. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:273. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:274. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:275. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:276. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:277. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:278. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:279. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:280. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:281. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:282. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:283. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:284. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:285. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:286. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:287. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:288. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:289. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:290. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:291. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:292. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:293. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:294. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:295. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:296. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:297. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:298. H Contains arrays.
[0148] Kabat CDR-H2 In some embodiments, the antibody comprises a V H The CDR-H2 sequence is an exemplary antibody or V HIn some embodiments, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of the Kabat CDR-H2 sequence of SEQ ID NOs: 308-366. H The sequence is the Kabat CDR-H2 sequence.
[0149] In some embodiments, the antibody comprises a V domain comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 181-239. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 181. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 182. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 183. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 184. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 185. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 186. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 187. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 188. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 189. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 190. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 191. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 192. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 193. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 194. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 195. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 196. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 197. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 198. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 199. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:200. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:201. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:202. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:203. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:204. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:205. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:206. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:207. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:208. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:209. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:210. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:211. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:212. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:213. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:214. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:215. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:216. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:217. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:218. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:219. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:220. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:221. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:222. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:223. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:224. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:225. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:226. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:227. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:228. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:229. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:230. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:231. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:232. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:233. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:234. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:235. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:236. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:237. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:238. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:239. H Contains arrays.
[0150] Kabat CDR-H1 In some embodiments, the antibody comprises a V H The CDR-H1 sequence is an exemplary antibody or V H In some embodiments, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of the Kabat CDR-H1 sequence of SEQ ID NOs: 308-366. H The sequence is the Kabat CDR-H1 sequence.
[0151] In some embodiments, the antibody comprises a V domain comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 63-121. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:63. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:64. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:65. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:66. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:67. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:68. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:69. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:70. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:71. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:72. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:73. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:74. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:75. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:76. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:77. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:78. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:79. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:80. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:81. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:82. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:83. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:84. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:85. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:86. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:87. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:88. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:89. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:90. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:91. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:92. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:93. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:94. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:95. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:96. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:97. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:98. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:99. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 100. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 101. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 102. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 103. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 104. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 105. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 106. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 107. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 108. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 109. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 110. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:111. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 112. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115. HIn some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 120. H In some embodiments, the antibody comprises a V sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 121. H Contains arrays.
[0152] 5.2.1.4.Kabat CDR-H3+Kabat CDR-H2 In some embodiments, the antibody comprises a V domain comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 240-298 and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 181-239. H In some embodiments, both the Kabat CDR-H3 sequence and the Kabat CDR-H2 sequence are identical to a single exemplary VDR-H3 sequence provided in the present disclosure. H For example, in some embodiments, both the Kabat CDR-H3 and the Kabat CDR-H2 are derived from a single exemplary VDR selected from SEQ ID NOs: 308-366. H It comes from the sequence.
[0153] 5.2.1.5.Kabat CDR-H3+Kabat CDR-H1 In some embodiments, the antibody comprises a V domain comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 240-298 and a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 63-121. H In some embodiments, both the Kabat CDR-H3 sequence and the Kabat CDR-H1 sequence are identical to a single exemplary VDR-H3 sequence provided in the present disclosure. H For example, in some embodiments, both the Kabat CDR-H3 and the Kabat CDR-H1 are derived from a single exemplary VDR selected from SEQ ID NOs: 308-366. H It comes from the sequence.
[0154] 5.2.1.6.Kabat CDR-H1+Kabat CDR-H2 In some embodiments, the antibody comprises a V domain comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 63-121 and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 181-239. H In some embodiments, both the Kabat CDR-H1 sequence and the Kabat CDR-H2 sequence are identical to a single exemplary VDR-H1 sequence provided in the present disclosure. H For example, in some embodiments, both Kabat CDR-H1 and Kabat CDR-H2 are derived from a single exemplary VDR selected from SEQ ID NOs: 308-366. H It comes from the sequence.
[0155] 5.2.1.7.Kabat CDR-H1+Kabat CDR-H2+Kabat CDR-H3 In some embodiments, the antibody comprises a V domain comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 63-121, a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 181-239, and a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 240-298. H In some embodiments, the Kabat CDR-H1 sequence, the Kabat CDR-H2 sequence, and the Kabat CDR-H3 sequence all contain a single exemplary VDR-H1 sequence provided in the present disclosure. H For example, in some embodiments, Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 are all derived from a single exemplary VDR selected from SEQ ID NOs: 308-366. H It comes from the sequence.
[0156] 5.2.1.8. V with Exemplary Kabat CDRs H Sequence variants In some embodiments, the V H The sequences include variants of the exemplary Kabat CDR-H3, CDR-H2 and / or CDR-H1 sequences provided in this disclosure.
[0157] In some embodiments, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a variant of the exemplary Kabat CDR-H3 sequence provided in this disclosure. In some embodiments, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary Kabat CDR-H3 sequences provided in this disclosure. In some embodiments, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary Kabat CDR-H3 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0158] In some embodiments, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a variant of the exemplary Kabat CDR-H2 sequence provided in this disclosure. In some embodiments, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary Kabat CDR-H2 sequences provided in this disclosure. In some embodiments, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of any of the exemplary Kabat CDR-H2 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0159] In some embodiments, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a variant of the exemplary Kabat CDR-H1 sequence provided in this disclosure. In some embodiments, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary Kabat CDR-H1 sequences provided in this disclosure. In some embodiments, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of any of the exemplary Kabat CDR-H1 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0160] 5.2.2. V with Exemplary Chothia CDRs H array In some embodiments, the antibody comprises a V sequence comprising one or more Chothia CDR-H sequences that comprise, consist of, or consist essentially of one or more exemplary Chothia CDR-H sequences provided in this disclosure and variants thereof. H Contains arrays.
[0161] Chothia CDR-H3 In some embodiments, the antibody comprises a V H The CDR-H3 sequence is an exemplary antibody or V H In some embodiments, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of the Chothia CDR-H3 sequence of SEQ ID NOs: 308-366. H The sequence is the Chothia CDR-H3 sequence.
[0162] In some embodiments, the antibody comprises a V polypeptide comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 240-298.H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:240. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:241. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:242. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:243. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:244. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:245. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:246. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:247. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:248. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:249. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:250. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:251.H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:252. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:253. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:254. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:255. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:256. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:257. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:258. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:259. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:260. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:261. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:262. HIn some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:263. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:264. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:265. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:266. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:267. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:268. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:269. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:270. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:271. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:272. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:273. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:274. HIn some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:275. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:276. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:277. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:278. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:279. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:280. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:281. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:282. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:283. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:284. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:285. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:286.H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:287. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:288. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:289. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:290. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:291. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:292. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:293. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:294. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:295. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:296. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:297. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:298.H Contains arrays.
[0163] Chothia CDR-H2 In some embodiments, the antibody comprises a V H The CDR-H2 sequence is an exemplary antibody or V H In some embodiments, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of the Chothia CDR-H2 sequence of SEQ ID NOs: 308-366. H The sequence is the Chothia CDR-H2 sequence.
[0164] In some embodiments, the antibody comprises a V polypeptide comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 122-180. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 122. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 123. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 125. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 126. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 127. HIn some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 128. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 129. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 130. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 131. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 132. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 133. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 134. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 135. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 136. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 137. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 138. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 139.H In some embodiments, the antibody comprises a V sequence comprising a Chothia H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 140. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:141. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 142. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 144. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 145. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 146. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 147. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 148. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 149. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 150. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 151.H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 152. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 153. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 154. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 155. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 156. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 157. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 158. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 159. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 160. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 161. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 162. HIn some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 163. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 164. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 165. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 166. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 167. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 168. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 169. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 170. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 171. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 172. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 173. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 174. HIn some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 175. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 176. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 177. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 178. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 179. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 180. H Contains arrays.
[0165] Chothia CDR-H1 In some embodiments, the antibody comprises a V H The CDR-H1 sequence is an exemplary antibody or V H In some embodiments, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of the Chothia CDR-H1 sequence of SEQ ID NOs: 308-366. H The sequence is the Chothia CDR-H1 sequence.
[0166] In some embodiments, the antibody comprises a V polypeptide comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 4-62. HIn some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:4. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:5. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:6. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:7. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:8. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:9. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:10. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:11. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:12. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 13. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:14. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:15. HIn some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:16. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:17. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:18. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:19. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:20. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:21. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:22. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:23. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:24. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:25. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:26. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:27. HIn some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:28. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:29. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:30. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:31. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:32. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:33. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:34. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:35. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:36. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:37. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:38. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:39. HIn some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:40. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:41. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:42. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:43. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:44. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:45. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:46. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:47. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:48. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:49. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:50. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:51. HIn some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:52. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:53. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:54. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:55. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:56. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:57. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:58. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:59. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:60. H In some embodiments, the antibody comprises a V sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:61. H In some embodiments, the antibody comprises a V sequence comprising a Chothia H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:62. H Contains arrays.
[0167] 5.2.2.4.Chothia CDR-H3+Chothia CDR-H2 In some embodiments, the antibody comprises a V domain comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 240-298, and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 122-180. H In some embodiments, both the Chothia CDR-H3 sequence and the Chothia CDR-H2 sequence comprise a single exemplary VDR-H3 sequence provided in the present disclosure. H For example, in some embodiments, both the Chothia CDR-H3 and the Chothia CDR-H2 are derived from a single exemplary VDR selected from SEQ ID NOs: 308-366. H It comes from the sequence.
[0168] 5.2.2.5.Chothia CDR-H3+Chothia CDR-H1 In some embodiments, the antibody comprises a V domain comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 240-298 and a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 4-62. H In some embodiments, both the Chothia CDR-H3 sequence and the Chothia CDR-H1 sequence comprise a single exemplary VDR-H3 sequence provided in the present disclosure. H For example, in some embodiments, both the Chothia CDR-H3 and the Chothia CDR-H1 are derived from a single exemplary VDR selected from SEQ ID NOs: 308-366. H It comes from the sequence.
[0169] 5.2.2.6.Chothia CDR-H1+Chothia CDR-H2 In some embodiments, the antibody comprises a V domain comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 4-62, and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 122-180. H In some embodiments, both the Chothia CDR-H1 sequence and the Chothia CDR-H2 sequence comprise a single exemplary VDR-H1 sequence provided in the present disclosure. H For example, in some embodiments, both Chothia CDR-H1 and Chothia CDR-H2 are derived from a single exemplary VDR selected from SEQ ID NOs: 308-366. H It comes from the sequence.
[0170] 5.2.2.7.Chothia CDR-H1+Chothia CDR-H2+Chothia CDR-H3 In some embodiments, the antibody comprises a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 4-62, a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 122-180, and a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 240-298. H In some embodiments, the Chothia CDR-H1 sequence, the Chothia CDR-H2 sequence, and the Chothia CDR-H3 sequence all contain a single exemplary VDR-H1 sequence provided in the present disclosure. H For example, in some embodiments, Chothia CDR-H1, Chothia CDR-H2, and Chothia CDR-H3 are all derived from a single exemplary VDR selected from SEQ ID NOs: 308-366. H It comes from the sequence.
[0171] 5.2.2.8. V with Exemplary Chothia CDRs H Sequence variants In some embodiments, the V H The sequences include variants of the exemplary Chothia CDR-H3, CDR-H2 and / or CDR-H1 sequences provided in this disclosure.
[0172] In some embodiments, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a variant of the exemplary Chothia CDR-H3 sequence provided in this disclosure. In some embodiments, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary Chothia CDR-H3 sequences provided in this disclosure. In some embodiments, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary Chothia CDR-H3 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0173] In some embodiments, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a variant of the exemplary Chothia CDR-H2 sequence provided in this disclosure. In some embodiments, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary Chothia CDR-H2 sequences provided in this disclosure. In some embodiments, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of any of the exemplary Chothia CDR-H2 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0174] In some embodiments, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a variant of the exemplary Chothia CDR-H1 sequence provided in this disclosure. In some embodiments, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary Chothia CDR-H1 sequences provided in this disclosure. In some embodiments, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of any of the exemplary Chothia CDR-H1 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0175] 5.3.V H array In some embodiments, the antibody comprises a VNA provided in SEQ ID NOs: 308-366. H It comprises, consists of, or consists essentially of the sequence.
[0176] In some embodiments, the antibody comprises, consists of, or consists essentially of a sequence selected from SEQ ID NOs: 308-366. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:308. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:309. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:310. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:311. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:312. HIn some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:313. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:314. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:315. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:316. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:317. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:318. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:319. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:320. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:321. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:322. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:323. H In some embodiments, the antibody comprises the V sequence comprising, consisting of, or consisting essentially of SEQ ID NO:324. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO: 325. H In some embodiments, the antibody comprises the V sequence comprising, consisting of, or consisting essentially of SEQ ID NO:326. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:327. HIn some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:328. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:329. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:330. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:331. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:332. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO: 333. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:334. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:335. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:336. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:337. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:338. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:339. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:340. H In some embodiments, the antibody comprises the V sequence comprising, consisting of, or consisting essentially of SEQ ID NO:341. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:342. HIn some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO:343. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO:344. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO:345. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:346. H In some embodiments, the antibody comprises the V sequence comprising, consisting of, or consisting essentially of SEQ ID NO:347. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:348. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:349. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 350. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO:351. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:352. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:353. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO:354. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:355. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:356. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:357. HIn some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:358. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:359. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:360. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:361. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:362. H In some embodiments, the antibody comprises a V sequence comprising, consisting of, or consisting essentially of SEQ ID NO:363. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:364. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:365. H In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:366. H Contains arrays.
[0177] 5.3.1.V H Sequence variants In some embodiments, the V H The sequences are the exemplary V H It may comprise, consist or consist essentially of a variant of the sequence.
[0178] In some embodiments, V H The sequences are the exemplary V H In some embodiments, the V H The sequences are the exemplary V HThe nucleic acid sequence may comprise, consist of, or consist essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.5% identity to any of the sequences.
[0179] In some embodiments, V H The sequence may be any of the exemplary V sequences provided herein having 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less amino acid substitutions. H In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0180] 5.4.CDR-L3 Sequence In some embodiments, the antibody is an exemplary antibody or V L In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of the CDR-L3 sequence of SEQ ID NOs: 367-369. L The sequence is the CDR-L3 sequence.
[0181] In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 305-307. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 305. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 306. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 307.
[0182] In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L3 sequence provided in this disclosure. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-L3 sequences provided in this disclosure. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0183] 5.5. Exemplary CDR-Containing V L array In some embodiments, the antibody comprises a V sequence comprising one or more CDR-L sequences that comprise, consist of, or consist essentially of one or more exemplary CDR-L sequences provided in this disclosure and variants thereof. L Contains arrays.
[0184] 5.5.1.CDR-L3 In some embodiments, the antibody comprises a V L The CDR-L3 sequence is an exemplary antibody or V L In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of the CDR-L3 sequence of SEQ ID NOs: 367-369. L The sequence is the CDR-L3 sequence.
[0185] In some embodiments, the antibody comprises a V domain comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 305-307. L In some embodiments, the antibody comprises a V sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:305. LIn some embodiments, the antibody comprises a V sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:306. L In some embodiments, the antibody comprises a V sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:307. L Contains arrays.
[0186] 5.5.2.CDR-L2 In some embodiments, the antibody comprises a V L The CDR-L2 sequence is an exemplary antibody or V L In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of the CDR-L2 sequence of SEQ ID NOs: 367-369. L The sequence is the CDR-L2 sequence.
[0187] In some embodiments, the antibody comprises a VDG comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 302-304. L In some embodiments, the antibody comprises a V sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:302. L In some embodiments, the antibody comprises a V sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:303. L In some embodiments, the antibody comprises a V sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 304. L Contains arrays.
[0188] 5.5.3.CDR-L1 In some embodiments, the antibody comprises a V L The CDR-L1 sequence is an exemplary antibody or V LIn some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of the CDR-L1 sequence of SEQ ID NOs: 367-369. L The sequence is the CDR-L1 sequence.
[0189] In some embodiments, the antibody comprises a VDG comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 299-301. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:299. L In some embodiments, the antibody comprises a V CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:300. L In some embodiments, the antibody comprises a V sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:301. L Contains arrays.
[0190] 5.5.4.CDR-L3+CDR-L2 In some embodiments, the antibody comprises a VDG comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 305-307, and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 302-304. L In some embodiments, both the CDR-L3 sequence and the CDR-L2 sequence comprise a single exemplary V sequence provided in the present disclosure. L For example, in some embodiments, both CDR-L3 and CDR-L2 are derived from a single exemplary V sequence selected from SEQ ID NOs: 367-369. L It comes from the sequence.
[0191] 5.5.5.CDR-L3+CDR-L1 In some embodiments, the antibody comprises a VDG comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 305-307, and a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 299-301. L In some embodiments, both the CDR-L3 sequence and the CDR-L1 sequence comprise a single exemplary V sequence provided in the present disclosure. L For example, in some embodiments, both CDR-L3 and CDR-L1 are derived from a single exemplary V sequence selected from SEQ ID NOs: 367-369. L It comes from the sequence.
[0192] 5.5.6.CDR-L1+CDR-L2 In some embodiments, the antibody comprises a VDG comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 299-301 and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 302-304. L In some embodiments, both the CDR-L1 sequence and the CDR-L2 sequence comprise a single exemplary V sequence provided in the present disclosure. L For example, in some embodiments, both CDR-L1 and CDR-L2 are derived from a single exemplary V sequence selected from SEQ ID NOs: 367-369. L It comes from the sequence.
[0193] 5.5.7.CDR-L1+CDR-L2+CDR-L3 In some embodiments, the antibody comprises a VL1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 299-301, a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 302-304, and a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 305-307. LIn some embodiments, the CDR-L1 sequence, the CDR-L2 sequence, and the CDR-L3 sequence all include a single exemplary V sequence provided in the present disclosure. L For example, in some embodiments, CDR-L1, CDR-L2, and CDR-L3 are all derived from a single exemplary V sequence selected from SEQ ID NOs: 367-369. L It comes from the sequence.
[0194] 5.5.8. EXEMPLARY CDR-L CONTAINING VL SEQUENCE VARIANTS In some embodiments, the V L The sequences include variants of the exemplary CDR-L3, CDR-L2 and / or CDR-L1 sequences provided in this disclosure.
[0195] In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L3 sequence provided in this disclosure. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-L3 sequences provided in this disclosure. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0196] In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L2 sequence provided in this disclosure. In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-L2 sequences provided in this disclosure. In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L2 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0197] In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L1 sequence provided in this disclosure. In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-L1 sequences provided in this disclosure. In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L1 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0198] 5.6.V L array In some embodiments, the antibody comprises a V L It comprises, consists of, or consists essentially of the sequence.
[0199] In some embodiments, the antibody comprises, consists of, or consists essentially of a sequence selected from SEQ ID NOs: 367-369. L In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:367. LIn some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:368. L In some embodiments, the antibody comprises, consists of, or consists essentially of SEQ ID NO:369. L Contains arrays.
[0200] 5.6.1.V L Sequence variants In some embodiments, the V L The sequences are the exemplary V L It may comprise, consist or consist essentially of a variant of the sequence.
[0201] In some embodiments, V L The sequences are the exemplary V L In some embodiments, the V L The sequences are the exemplary V L The nucleic acid sequence may comprise, consist of, or consist essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.5% identity to any of the sequences.
[0202] In some embodiments, V L The sequence may be any of the exemplary V sequences provided herein having 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less amino acid substitutions. L In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0203] 5.7.Versus 5.7.1.CDR-H3 and CDR-L3 Pairing In some embodiments, the antibody comprises a CDR-H3 sequence and a CDR-L3 sequence. In some aspects, the CDR-H3 sequence is H and the CDR-L3 sequence is part of V L is part of.
[0204]
[0204] In some aspects, the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 240-298, and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 305-307.
[0205]
[0205] In some embodiments, the CDR-H3 and CDR-L3 pairs are selected from the group consisting of SEQ ID NO:305 and SEQ ID NO:240; SEQ ID NO:305 and SEQ ID NO:241; SEQ ID NO:305 and SEQ ID NO:242; SEQ ID NO:305 and SEQ ID NO:243; SEQ ID NO:305 and SEQ ID NO:244; SEQ ID NO:305 and SEQ ID NO:245; SEQ ID NO:305 and SEQ ID NO:246; SEQ ID NO:305 and SEQ ID NO:247; SEQ ID NO:305 and SEQ ID NO:248; SEQ ID NO:305 and SEQ ID NO:249; SEQ ID NO:305 and SEQ ID NO:250; SEQ ID NO:305 and SEQ ID NO:251; SEQ ID NO:305 and SEQ ID NO: 252;SEQ ID NO:305 and SEQ ID NO:253;SEQ ID NO:305 and SEQ ID NO:254;SEQ ID NO:305 and SEQ ID NO:255;SEQ ID NO:305 and SEQ ID NO:256;SEQ ID NO:305 and SEQ ID NO:257;SEQ ID NO:305 and SEQ ID NO:258;SEQ ID NO:305 and SEQ ID NO:259;SEQ ID NO:305 and SEQ ID NO:260;SEQ ID NO:305 and SEQ ID NO:261;SEQ ID NO:305 and SEQ ID NO:262;SEQ ID NO:305 and SEQ ID NO:263;SEQ ID NO:305 and SEQ ID NO:264;SEQ ID NO:305 and SEQ ID NO:265;SEQ ID NO:305 and SEQ ID NO:266;SEQ ID NO: SEQ ID NO:305 and SEQ ID NO:267; SEQ ID NO:305 and SEQ ID NO:268; SEQ ID NO:305 and SEQ ID NO:269; SEQ ID NO:305 and SEQ ID NO:270; SEQ ID NO:305 and SEQ ID NO:271; SEQ ID NO:305 and SEQ ID NO:272; SEQ ID NO:305 and SEQ ID NO:273; SEQ ID NO:305 and SEQ ID NO:274; SEQ ID NO:305 and SEQ ID NO:275; SEQ ID NO:305 and SEQ ID NO:276; SEQ ID NO:305 and SEQ ID NO:277; SEQ ID NO:305 and SEQ ID NO:278; SEQ ID NO:305 and SEQ ID NO:279; SEQ ID NO:305 and SEQ ID NO:280; SEQ ID NO:305 and Sequence number 281; SEQ ID NO:305 and SEQ ID NO:282; SEQ ID NO:305 and SEQ ID NO:283; SEQ ID NO:305 and SEQ ID NO:284; SEQ ID NO:305 and SEQ ID NO:285; SEQ ID NO:305 and SEQ ID NO:286; SEQ ID NO:305 and SEQ ID NO:287; SEQ ID NO:305 and SEQ ID NO:288; SEQ ID NO:305 and SEQ ID NO:289; SEQ ID NO:305 and SEQ ID NO:290; SEQ ID NO:305 and SEQ ID NO:291; SEQ ID NO:305 and SEQ ID NO:292; SEQ ID NO:305 and SEQ ID NO:293; SEQ ID NO:305 and SEQ ID NO:294; SEQ ID NO:305 and SEQ ID NO:295;Selected from SEQ ID NO:305 and SEQ ID NO:296; SEQ ID NO:305 and SEQ ID NO:297; and SEQ ID NO:305 and SEQ ID NO:298.
[0206]
[0206] In some embodiments, the CDR-H3 and CDR-L3 pairs are selected from the group consisting of SEQ ID NO:306 and SEQ ID NO:240; SEQ ID NO:306 and SEQ ID NO:241; SEQ ID NO:306 and SEQ ID NO:242; SEQ ID NO:306 and SEQ ID NO:243; SEQ ID NO:306 and SEQ ID NO:244; SEQ ID NO:306 and SEQ ID NO:245; SEQ ID NO:306 and SEQ ID NO:246; SEQ ID NO:306 and SEQ ID NO:247; SEQ ID NO:306 and SEQ ID NO:248; SEQ ID NO:306 and SEQ ID NO:249; SEQ ID NO:306 and SEQ ID NO:250; SEQ ID NO:306 and SEQ ID NO:251; SEQ ID NO:306 and SEQ ID NO: 252;SEQ ID NO:306 and SEQ ID NO:253;SEQ ID NO:306 and SEQ ID NO:254;SEQ ID NO:306 and SEQ ID NO:255;SEQ ID NO:306 and SEQ ID NO:256;SEQ ID NO:306 and SEQ ID NO:257;SEQ ID NO:306 and SEQ ID NO:258;SEQ ID NO:306 and SEQ ID NO:259;SEQ ID NO:306 and SEQ ID NO:260;SEQ ID NO:306 and SEQ ID NO:261;SEQ ID NO:306 and SEQ ID NO:262;SEQ ID NO:306 and SEQ ID NO:263;SEQ ID NO:306 and SEQ ID NO:264;SEQ ID NO:306 and SEQ ID NO:265;SEQ ID NO:306 and SEQ ID NO:266;SEQ ID NO: SEQ ID NO:306 and SEQ ID NO:267; SEQ ID NO:306 and SEQ ID NO:268; SEQ ID NO:306 and SEQ ID NO:269; SEQ ID NO:306 and SEQ ID NO:270; SEQ ID NO:306 and SEQ ID NO:271; SEQ ID NO:306 and SEQ ID NO:272; SEQ ID NO:306 and SEQ ID NO:273; SEQ ID NO:306 and SEQ ID NO:274; SEQ ID NO:306 and SEQ ID NO:275; SEQ ID NO:306 and SEQ ID NO:276; SEQ ID NO:306 and SEQ ID NO:277; SEQ ID NO:306 and SEQ ID NO:278; SEQ ID NO:306 and SEQ ID NO:279; SEQ ID NO:306 and SEQ ID NO:280; SEQ ID NO:306 and Sequence number 281; SEQ ID NO:306 and SEQ ID NO:282; SEQ ID NO:306 and SEQ ID NO:283; SEQ ID NO:306 and SEQ ID NO:284; SEQ ID NO:306 and SEQ ID NO:285; SEQ ID NO:306 and SEQ ID NO:286; SEQ ID NO:306 and SEQ ID NO:287; SEQ ID NO:306 and SEQ ID NO:288; SEQ ID NO:306 and SEQ ID NO:289; SEQ ID NO:306 and SEQ ID NO:290; SEQ ID NO:306 and SEQ ID NO:291; SEQ ID NO:306 and SEQ ID NO:292; SEQ ID NO:306 and SEQ ID NO:293; SEQ ID NO:306 and SEQ ID NO:294; SEQ ID NO:306 and SEQ ID NO:295;Selected from SEQ ID NO:306 and SEQ ID NO:296; SEQ ID NO:306 and SEQ ID NO:297; and SEQ ID NO:306 and SEQ ID NO:298.
[0207]
[0207] In some embodiments, the CDR-H3 and CDR-L3 pairs are selected from the group consisting of SEQ ID NO:307 and SEQ ID NO:240; SEQ ID NO:307 and SEQ ID NO:241; SEQ ID NO:307 and SEQ ID NO:242; SEQ ID NO:307 and SEQ ID NO:243; SEQ ID NO:307 and SEQ ID NO:244; SEQ ID NO:307 and SEQ ID NO:245; SEQ ID NO:307 and SEQ ID NO:246; SEQ ID NO:307 and SEQ ID NO:247; SEQ ID NO:307 and SEQ ID NO:248; SEQ ID NO:307 and SEQ ID NO:249; SEQ ID NO:307 and SEQ ID NO:250; SEQ ID NO:307 and SEQ ID NO:251; SEQ ID NO:307 and SEQ ID NO: 252;SEQ ID NO:307 and SEQ ID NO:253;SEQ ID NO:307 and SEQ ID NO:254;SEQ ID NO:307 and SEQ ID NO:255;SEQ ID NO:307 and SEQ ID NO:256;SEQ ID NO:307 and SEQ ID NO:257;SEQ ID NO:307 and SEQ ID NO:258;SEQ ID NO:307 and SEQ ID NO:259;SEQ ID NO:307 and SEQ ID NO:260;SEQ ID NO:307 and SEQ ID NO:261;SEQ ID NO:307 and SEQ ID NO:262;SEQ ID NO:307 and SEQ ID NO:263;SEQ ID NO:307 and SEQ ID NO:264;SEQ ID NO:307 and SEQ ID NO:265;SEQ ID NO:307 and SEQ ID NO:266;SEQ ID NO: SEQ ID NO:307 and SEQ ID NO:267; SEQ ID NO:307 and SEQ ID NO:268; SEQ ID NO:307 and SEQ ID NO:269; SEQ ID NO:307 and SEQ ID NO:270; SEQ ID NO:307 and SEQ ID NO:271; SEQ ID NO:307 and SEQ ID NO:272; SEQ ID NO:307 and SEQ ID NO:273; SEQ ID NO:307 and SEQ ID NO:274; SEQ ID NO:307 and SEQ ID NO:275; SEQ ID NO:307 and SEQ ID NO:276; SEQ ID NO:307 and SEQ ID NO:277; SEQ ID NO:307 and SEQ ID NO:278; SEQ ID NO:307 and SEQ ID NO:279; SEQ ID NO:307 and SEQ ID NO:280; SEQ ID NO:307 and Sequence number 281; SEQ ID NO:307 and SEQ ID NO:282; SEQ ID NO:307 and SEQ ID NO:283; SEQ ID NO:307 and SEQ ID NO:284; SEQ ID NO:307 and SEQ ID NO:285; SEQ ID NO:307 and SEQ ID NO:286; SEQ ID NO:307 and SEQ ID NO:287; SEQ ID NO:307 and SEQ ID NO:288; SEQ ID NO:307 and SEQ ID NO:289; SEQ ID NO:307 and SEQ ID NO:290; SEQ ID NO:307 and SEQ ID NO:291; SEQ ID NO:307 and SEQ ID NO:292; SEQ ID NO:307 and SEQ ID NO:293; SEQ ID NO:307 and SEQ ID NO:294; SEQ ID NO:307 and SEQ ID NO:295;Selected from SEQ ID NO:307 and SEQ ID NO:296; SEQ ID NO:307 and SEQ ID NO:297; and SEQ ID NO:307 and SEQ ID NO:298.
[0208] 5.7.1.1. CDR-H3 and CDR-L3 Paired Mutations
[0208] In some embodiments, the CDR-H3 and CDR-L3 pairs provided herein comprise variants of the exemplary CDR-H3 and / or CDR-L1 sequences provided herein.
[0209] In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-H3 sequence provided in this disclosure. In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-H3 sequences provided in this disclosure. In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-H3 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0210] In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L3 sequence provided in this disclosure. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-L3 sequences provided in this disclosure. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0211] 5.7.2.CDR-H1 and CDR-L1 Pairing In some embodiments, the antibody comprises a CDR-H1 sequence and a CDR-L1 sequence. In some aspects, the CDR-H1 sequence is H and the CDR-L1 sequence is part of V L is part of.
[0212]
[0212] In some aspects, the CDR-H1 sequence is a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 4-62, and the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 299-301.
[0213]
[0213] In some aspects, the CDR-H1 sequence is a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 63-121, and the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 299-301.
[0214] 5.7.2.1. CDR-H1 and CDR-L1 Paired Mutations
[0214] In some embodiments, the CDR-H1 and CDR-L1 pairs provided herein comprise variants of the exemplary CDR-H1 and / or CDR-L1 sequences provided herein.
[0215] In some embodiments, the CDR-H1 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-H1 sequence provided in this disclosure. In some embodiments, the CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-H1 sequences provided in this disclosure. In some embodiments, the CDR-H1 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-H1 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0216] In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L1 sequence provided in this disclosure. In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-L1 sequences provided in this disclosure. In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L1 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0217] 5.7.3.CDR-H2 and CDR-L2 Pairing In some embodiments, the antibody comprises a CDR-H2 sequence and a CDR-L2 sequence. In some aspects, the CDR-H2 sequence is H and the CDR-L2 sequence is part of V L is part of.
[0218]
[0218] In some embodiments, the CDR-H2 sequence is a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 122-180, and the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 302-304.
[0219]
[0219] In some aspects, the CDR-H1 sequence is a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 181-239, and the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 302-304.
[0220] 5.7.3.1. CDR-H2 and CDR-L2 Paired Mutations
[0220] In some embodiments, the CDR-H2 and CDR-L2 pairs provided herein comprise variants of the exemplary CDR-H2 and / or CDR-L2 sequences provided herein.
[0221] In some embodiments, the CDR-H2 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-H2 sequence provided in this disclosure. In some embodiments, the CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-H2 sequences provided in this disclosure. In some embodiments, the CDR-H2 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-H2 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0222] In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L2 sequence provided in this disclosure. In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-L2 sequences provided in this disclosure. In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L2 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0223] 5.7.4.V H and V L Against In some embodiments, the antibody comprises H Sequence and V L Contains arrays.
[0224] In some embodiments, VH The sequence comprises, consists of, or essentially consists of SEQ ID NOs: 308-366. H is an array, V L The sequence comprises, consists of, or essentially consists of SEQ ID NOs: 367-369. L It is an array.
[0225] In some embodiments, V H and V LPairs with are SEQ ID NO:367 and SEQ ID NO:308; SEQ ID NO:367 and SEQ ID NO:309; SEQ ID NO:367 and SEQ ID NO:310; SEQ ID NO:367 and SEQ ID NO:311; SEQ ID NO:367 and SEQ ID NO:312; SEQ ID NO:367 and SEQ ID NO:313; SEQ ID NO:367 and SEQ ID NO:314; SEQ ID NO:367 and SEQ ID NO:315; SEQ ID NO:367 and SEQ ID NO:316; SEQ ID NO:367 and SEQ ID NO:317; SEQ ID NO:367 and SEQ ID NO:318; SEQ ID NO:367 and SEQ ID NO:319; SEQ ID NO:367 and SEQ ID NO:320; SEQ ID NO:367 and SEQ ID NO:321; SEQ ID NO: 367 and SEQ ID NO:322; SEQ ID NO:367 and SEQ ID NO:323; SEQ ID NO:367 and SEQ ID NO:324; SEQ ID NO:367 and SEQ ID NO:325; SEQ ID NO:367 and SEQ ID NO:326; SEQ ID NO:367 and SEQ ID NO:327; SEQ ID NO:367 and SEQ ID NO:328; SEQ ID NO:367 and SEQ ID NO:329; SEQ ID NO:367 and SEQ ID NO:330; SEQ ID NO:367 and SEQ ID NO:331; SEQ ID NO:367 and SEQ ID NO:332; SEQ ID NO:367 and SEQ ID NO:333; SEQ ID NO:367 and SEQ ID NO:334; SEQ ID NO:367 and SEQ ID NO:335; SEQ ID NO:367 and SEQ ID NO:3 36;SEQ ID NO:367 and SEQ ID NO:337;SEQ ID NO:367 and SEQ ID NO:338;SEQ ID NO:367 and SEQ ID NO:339;SEQ ID NO:367 and SEQ ID NO:340;SEQ ID NO:367 and SEQ ID NO:341;SEQ ID NO:367 and SEQ ID NO:342;SEQ ID NO:367 and SEQ ID NO:343;SEQ ID NO:367 and SEQ ID NO:344;SEQ ID NO:367 and SEQ ID NO:345;SEQ ID NO:367 and SEQ ID NO:346;SEQ ID NO:367 and SEQ ID NO:347;SEQ ID NO:367 and SEQ ID NO:348;SEQ ID NO:367 and SEQ ID NO:349;SEQ ID NO:367 and SEQ ID NO:350;SEQ ID NO:367 and SEQ ID NO:351; SEQ ID NO:367 and SEQ ID NO:352; SEQ ID NO:367 and SEQ ID NO:353; SEQ ID NO:367 and SEQ ID NO:354; SEQ ID NO:367 and SEQ ID NO:355; SEQ ID NO:367 and SEQ ID NO:356; SEQ ID NO:367 and SEQ ID NO:357; SEQ ID NO:367 and SEQ ID NO:358; SEQ ID NO:367 and SEQ ID NO:359; SEQ ID NO:367 and SEQ ID NO:360; SEQ ID NO:367 and SEQ ID NO:361; SEQ ID NO:367 and SEQ ID NO:362; SEQ ID NO:367 and SEQ ID NO:363; SEQ ID NO:367 and SEQ ID NO:364; SEQ ID NO:367 and SEQ ID NO:365;and selected from SEQ ID NO: 367 and SEQ ID NO: 366;
[0226] In some embodiments, V H and V LPairs with are SEQ ID NO:368 and SEQ ID NO:308; SEQ ID NO:368 and SEQ ID NO:309; SEQ ID NO:368 and SEQ ID NO:310; SEQ ID NO:368 and SEQ ID NO:311; SEQ ID NO:368 and SEQ ID NO:312; SEQ ID NO:368 and SEQ ID NO:313; SEQ ID NO:368 and SEQ ID NO:314; SEQ ID NO:368 and SEQ ID NO:315; SEQ ID NO:368 and SEQ ID NO:316; SEQ ID NO:368 and SEQ ID NO:317; SEQ ID NO:368 and SEQ ID NO:318; SEQ ID NO:368 and SEQ ID NO:319; SEQ ID NO:368 and SEQ ID NO:320; SEQ ID NO:368 and SEQ ID NO:321; SEQ ID NO: 368 and SEQ ID NO:322; SEQ ID NO:368 and SEQ ID NO:323; SEQ ID NO:368 and SEQ ID NO:324; SEQ ID NO:368 and SEQ ID NO:325; SEQ ID NO:368 and SEQ ID NO:326; SEQ ID NO:368 and SEQ ID NO:327; SEQ ID NO:368 and SEQ ID NO:328; SEQ ID NO:368 and SEQ ID NO:329; SEQ ID NO:368 and SEQ ID NO:330; SEQ ID NO:368 and SEQ ID NO:331; SEQ ID NO:368 and SEQ ID NO:332; SEQ ID NO:368 and SEQ ID NO:333; SEQ ID NO:368 and SEQ ID NO:334; SEQ ID NO:368 and SEQ ID NO:335; SEQ ID NO:368 and SEQ ID NO:3 36;SEQ ID NO:368 and SEQ ID NO:337;SEQ ID NO:368 and SEQ ID NO:338;SEQ ID NO:368 and SEQ ID NO:339;SEQ ID NO:368 and SEQ ID NO:340;SEQ ID NO:368 and SEQ ID NO:341;SEQ ID NO:368 and SEQ ID NO:342;SEQ ID NO:368 and SEQ ID NO:343;SEQ ID NO:368 and SEQ ID NO:344;SEQ ID NO:368 and SEQ ID NO:345;SEQ ID NO:368 and SEQ ID NO:346;SEQ ID NO:368 and SEQ ID NO:347;SEQ ID NO:368 and SEQ ID NO:348;SEQ ID NO:368 and SEQ ID NO:349;SEQ ID NO:368 and SEQ ID NO:350;SEQ ID NO:368 and SEQ ID NO:351; SEQ ID NO:368 and SEQ ID NO:352; SEQ ID NO:368 and SEQ ID NO:353; SEQ ID NO:368 and SEQ ID NO:354; SEQ ID NO:368 and SEQ ID NO:355; SEQ ID NO:368 and SEQ ID NO:356; SEQ ID NO:368 and SEQ ID NO:357; SEQ ID NO:368 and SEQ ID NO:358; SEQ ID NO:368 and SEQ ID NO:359; SEQ ID NO:368 and SEQ ID NO:360; SEQ ID NO:368 and SEQ ID NO:361; SEQ ID NO:368 and SEQ ID NO:362; SEQ ID NO:368 and SEQ ID NO:363; SEQ ID NO:368 and SEQ ID NO:364; SEQ ID NO:368 and SEQ ID NO:365;and selected from SEQ ID NO: 368 and SEQ ID NO: 366;
[0227] In some embodiments, V H and V LPairs with are SEQ ID NO:369 and SEQ ID NO:308; SEQ ID NO:369 and SEQ ID NO:309; SEQ ID NO:369 and SEQ ID NO:310; SEQ ID NO:369 and SEQ ID NO:311; SEQ ID NO:369 and SEQ ID NO:312; SEQ ID NO:369 and SEQ ID NO:313; SEQ ID NO:369 and SEQ ID NO:314; SEQ ID NO:369 and SEQ ID NO:315; SEQ ID NO:369 and SEQ ID NO:316; SEQ ID NO:369 and SEQ ID NO:317; SEQ ID NO:369 and SEQ ID NO:318; SEQ ID NO:369 and SEQ ID NO:319; SEQ ID NO:369 and SEQ ID NO:320; SEQ ID NO:369 and SEQ ID NO:321; SEQ ID NO: 369 and SEQ ID NO:322; SEQ ID NO:369 and SEQ ID NO:323; SEQ ID NO:369 and SEQ ID NO:324; SEQ ID NO:369 and SEQ ID NO:325; SEQ ID NO:369 and SEQ ID NO:326; SEQ ID NO:369 and SEQ ID NO:327; SEQ ID NO:369 and SEQ ID NO:328; SEQ ID NO:369 and SEQ ID NO:329; SEQ ID NO:369 and SEQ ID NO:330; SEQ ID NO:369 and SEQ ID NO:331; SEQ ID NO:369 and SEQ ID NO:332; SEQ ID NO:369 and SEQ ID NO:333; SEQ ID NO:369 and SEQ ID NO:334; SEQ ID NO:369 and SEQ ID NO:335; SEQ ID NO:369 and SEQ ID NO:3 36;SEQ ID NO:369 and SEQ ID NO:337;SEQ ID NO:369 and SEQ ID NO:338;SEQ ID NO:369 and SEQ ID NO:339;SEQ ID NO:369 and SEQ ID NO:340;SEQ ID NO:369 and SEQ ID NO:341;SEQ ID NO:369 and SEQ ID NO:342;SEQ ID NO:369 and SEQ ID NO:343;SEQ ID NO:369 and SEQ ID NO:344;SEQ ID NO:369 and SEQ ID NO:345;SEQ ID NO:369 and SEQ ID NO:346;SEQ ID NO:369 and SEQ ID NO:347;SEQ ID NO:369 and SEQ ID NO:348;SEQ ID NO:369 and SEQ ID NO:349;SEQ ID NO:369 and SEQ ID NO:350;SEQ ID NO:369 and SEQ ID NO:351; SEQ ID NO:369 and SEQ ID NO:352; SEQ ID NO:369 and SEQ ID NO:353; SEQ ID NO:369 and SEQ ID NO:354; SEQ ID NO:369 and SEQ ID NO:355; SEQ ID NO:369 and SEQ ID NO:356; SEQ ID NO:369 and SEQ ID NO:357; SEQ ID NO:369 and SEQ ID NO:358; SEQ ID NO:369 and SEQ ID NO:359; SEQ ID NO:369 and SEQ ID NO:360; SEQ ID NO:369 and SEQ ID NO:361; SEQ ID NO:369 and SEQ ID NO:362; SEQ ID NO:369 and SEQ ID NO:363; SEQ ID NO:369 and SEQ ID NO:364; SEQ ID NO:369 and SEQ ID NO:365;and selected from SEQ ID NO: 369 and SEQ ID NO: 366;
[0228] 5.7.4.1.V H and V L and variants In some embodiments, the V H and V L The pairing with is shown in the exemplary V H and / or V L Includes variants of the sequence.
[0229] In some embodiments, V H The sequences are the exemplary V H In some embodiments, the V H The sequences are the exemplary V H The nucleic acid sequence may comprise, consist of, or consist essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.1% identity to any of the sequences.
[0230] In some embodiments, V H The sequence may be any of the exemplary V sequences provided herein having 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less amino acid substitutions. H In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0231] In some embodiments, V L The sequences are the exemplary V L In some embodiments, the V L The sequences are the exemplary V LThe nucleic acid sequence may comprise, consist of, or consist essentially of a sequence having at least 95%, 96%, 97%, 98%, 99% or 99.5% identity to any of the sequences.
[0232] In some embodiments, V L The sequence may be any of the exemplary V sequences provided herein having 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less amino acid substitutions. L In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0233] 5.8. Antibodies containing all six CDRs In some embodiments, the antibody comprises a CDR-H1 sequence, a CDR-H2 sequence, a CDR-H3 sequence, a CDR-L1 sequence, and a CDR-L3 sequence. H (For CDR-H) or V L (In the case of CDR-L)
[0234]
[0234] In some embodiments, the CDR-H1 sequence is a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 4-62; the CDR-H2 sequence is a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 122-180; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 240-298; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 299-301; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 302-304; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 305-307.
[0235]
[0235] In some embodiments, the CDR-H1 sequence is a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 19; the CDR-H2 sequence is a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 137; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 255; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 299-301; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 302-304; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 305-307.
[0236]
[0236] In some embodiments, the CDR-H1 sequence is a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:58; the CDR-H2 sequence is a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:176; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:294; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs:299-301; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs:302-304; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs:305-307.
[0237]
[0237] In some aspects, the CDR-H1 sequence is a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 63-121; the CDR-H2 sequence is a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 181-239; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 240-298; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 299-301; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 302-304; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 305-307.
[0238]
[0238] In some embodiments, the CDR-H1 sequence is a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:78; the CDR-H2 sequence is a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:196; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO:255; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs:299-301; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs:302-304; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs:305-307.
[0239]
[0239] In some aspects, the CDR-H1 sequence is a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117; the CDR-H2 sequence is a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 235; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 294; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 299-301; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 302-304; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 305-307.
[0240] 5.8.1. Antibody Variants Containing All Six CDRs
[0240] In some embodiments, the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3 provided herein comprise variants of the exemplary CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and / or CDR-L3 sequences provided herein.
[0241] In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a variant of the exemplary Chothia or Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary Chothia or Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of any of the exemplary Chothia or Kabat CDR-H1 sequences provided in this disclosure with one, two or three amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0242] In some embodiments, the CDR-H2 sequence comprises, consists of, or consists essentially of a variant of the exemplary Chothia or Kabat CDR-H2 sequence provided in this disclosure. In some embodiments, the CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary Chothia or Kabat CDR-H2 sequences provided in this disclosure. In some embodiments, the CDR-H2 sequence comprises, consists of, or consists essentially of any of the exemplary Chothia or Kabat CDR-H2 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0243] In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-H3 sequence provided in this disclosure. In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-H3 sequences provided in this disclosure. In some embodiments, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-H3 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0244] In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L1 sequence provided in this disclosure. In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-L1 sequences provided in this disclosure. In some embodiments, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L1 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0245] In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L2 sequence provided in this disclosure. In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-L2 sequences provided in this disclosure. In some embodiments, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L2 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0246] In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of the exemplary CDR-L3 sequence provided in this disclosure. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90% or 95% identity with any of the exemplary CDR-L3 sequences provided in this disclosure. In some embodiments, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the exemplary CDR-L3 sequences provided in this disclosure with one, two or three amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0247] 7. Affinity In some embodiments, K D The affinity of the antibody for the folate receptor α, as shown by -5 Less than M, about 10 -6 Less than M, about 10 -7 Less than M, about 10 -8 Less than M, about 10 -9 Less than M, about 10 -10 Less than M, about 10 -11 Less than M or about 10 -12 In some embodiments, the affinity of the antibody is less than about 10 -7 M~10 -11 In some embodiments, the affinity of the antibody is about 10 -7 M~10 -10 In some embodiments, the affinity of the antibody is about 10 -7 M~10 -9 In some embodiments, the affinity of the antibody is about 10 -7 M~10 -8 In some embodiments, the affinity of the antibody is about 10 -8 M~10 -11 In some embodiments, the affinity of the antibody is about 10 -8 M~10 -10 In some embodiments, the affinity of the antibody is about 10 -9 M~10 -11In some embodiments, the affinity of the antibody is about 10 -9 M~10 -10 It's M.
[0248] In some embodiments, the K is measured by surface plasmon resonance at 25° C. D The affinity of the antibody for the human folate receptor α, as shown by -9 M ~ approx. 2.21×10 -9 In some embodiments, the K is measured by surface plasmon resonance at 25° C. D The affinity of the antibody for the human folate receptor α, as shown by -10 M ~ approx. 1.70×10 -8 In some embodiments, the K is measured by surface plasmon resonance at 25° C. D The affinity of the antibody for the human folate receptor α, as shown by -10 M ~ approx. 2.58×10 -8 In some embodiments, the affinity of the antibody for human folate receptor alpha is greater than or equal to the K reported for human folate receptor alpha in the Examples below. D The value is approximately one of
[0249] In some embodiments, the antibody has a nucleotide sequence of at least about 10 4 M -1 × seconds -1 k a In some embodiments, the antibody has a 5 M -1 × seconds -1 k a In some embodiments, the antibody has a 6 M -1 × seconds -1 k a In some embodiments, the antibody has a 7 M -1 × seconds -1 k a In some embodiments, the antibody has a 8M -1 × seconds -1 k a In some embodiments, the antibody has a 9 M -1 × seconds -1 k a In some embodiments, the antibody has a 4 M -1 × seconds -1 ~about 10 10 M -1 × seconds -1 k a In some embodiments, the antibody has a 5 M -1 × seconds -1 ~about 10 10 M -1 × seconds -1 k a In some embodiments, the antibody has a 6 M -1 × seconds -1 ~about 10 10 M -1 × seconds -1 k a In some embodiments, the antibody has a 7 M -1 × seconds -1 ~about 10 10 M -1 × seconds -1 k a has.
[0250] In some embodiments, the antibody has a binding affinity to the human folate receptor alpha of about 4.44×10 as measured by surface plasmon resonance at 25° C. 5 M -1 × seconds -1 ~Approx. 1.61×10 5 M -1 × seconds -1 k a In some embodiments, the antibody has a molecular weight of about 2.90×10 when bound to the human folate receptor alpha, as measured by surface plasmon resonance at 25° C. 5 M -1 × seconds -1 ~Approx. 9.64×10 9 M -1× seconds -1 k a In some embodiments, the antibody, when bound to human folate receptor alpha, has the k reported for human folate receptor alpha in the Examples below. a Nearly any value of k a has.
[0251] In some embodiments, the antibody is -5 seconds -1 The following k d In some embodiments, the antibody has a -4 seconds -1 The following k d In some embodiments, the antibody has a -3 seconds -1 The following k d In some embodiments, the antibody has a -2 seconds -1 ~about 10 -5 seconds -1 k d In some embodiments, the antibody has a -2 seconds -1 ~about 10 -4 seconds -1 k d In some embodiments, the antibody has a -3 seconds -1 ~about 10 -5 seconds -1 k d has.
[0252] In some embodiments, the antibody, when separated from the human folate receptor alpha, has a molecular weight of about 8.66×10 as measured by surface plasmon resonance at 25° C. -4 seconds -1 ~Approx. 1.08×10 -2 seconds -1 k d In some embodiments, the antibody, when separated from the human folate receptor alpha, has a molecular weight of about 2.28×10 at 25° C. as measured by surface plasmon resonance. -4 seconds -1 ~Approx. 4.82×10 1 seconds -1 k dIn some embodiments, the antibody, when isolated from human folate receptor alpha, has the k reported for human folate receptor alpha in the Examples below. d Nearly any value of k d has.
[0253] In some embodiments, the K is measured by surface plasmon resonance at 25° C. D The affinity of the antibody for the cynomolgus monkey folate receptor α, as shown by -9 M ~ approx. 2.84×10 -9 In some embodiments, the affinity of the antibody for the cynomolgus monkey folate receptor alpha is K M reported for the cynomolgus monkey folate receptor alpha in the Examples below. D The value is approximately one of
[0254] In some embodiments, the K is measured by surface plasmon resonance at 25° C. D The affinity of the antibody for mouse folate receptor α, as shown by -9 M ~ approx. 9.07×10 -8 In some embodiments, the affinity of the antibody for mouse folate receptor alpha is greater than or equal to the K reported for mouse folate receptor alpha in the Examples below. D The value is approximately one of
[0255] In some embodiments, K D , k a and k d is measured at 25° C. In some embodiments, K D , k a and k d is measured by surface plasmon resonance. D , k a and k d is measured by the methods described in the Examples provided herein.
[0256] 8. Epitope Binding In some embodiments, the antibody binds to the same epitope as an antibody comprising any one of SEQ ID NOs: 308-366. H -V L In some embodiments, the antibody competes for epitope binding with an antibody comprising any of SEQ ID NOs: 308-366. H -V L It competes for epitope binding with antibodies comprising either of the pair.
[0257] 9. Glycosylation variants
[0257] In certain embodiments, an antibody may be modified to increase, decrease, or eliminate the extent to which it is glycosylated. Glycosylation of polypeptides is typically either "N-linked" or "O-linked."
[0258] "N-linked" glycosylation refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site.
[0259]
[0259] "O-linked" glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine can also be used.
[0260]
[0260] Addition or deletion of N-linked glycosylation sites to an antibody can be accomplished by altering the amino acid sequence to create or remove one or more of the above tripeptide sequences. Addition or deletion of O-linked glycosylation sites can be accomplished by adding, deleting, or substituting one or more serine or threonine residues within or (optionally) to the antibody sequence.
[0261] 10.Fc variants In certain embodiments, amino acid modifications may be introduced into the Fc region of the antibodies provided herein to generate Fc region variants. In certain embodiments, the Fc region variants retain some, but not all, effector functions. Such antibodies may be useful, for example, in applications where the half-life of the antibody in vivo is important, but certain effector functions are unnecessary or harmful. Examples of effector functions include complement-dependent cytotoxicity (CDC) and antibody-directed complement-mediated cytotoxicity (ADCC). Numerous substitutions or groups of substitutions or deletions that alter effector functions are known in the art.
[0262] In some embodiments, Fc is C H In some embodiments, the Fc comprises one or more modifications in at least one of the three sequences. H At least one of the two sequences contains one or more modifications. For example, the Fc may contain one or modifications selected from the group consisting of V262E, V262D, V262K, V262R, V262S, V264S, V303R, and V305R. In some embodiments, the Fc is a single polypeptide. In some embodiments, the Fc is a multi-peptide, such as, for example, two polypeptides. Exemplary modifications of the Fc region are described, for example, in International Patent Application No. PCT / US2017 / 037545, filed June 14, 2017.
[0263]
[0263] Changes in CDC and / or ADCC activity can be confirmed using in vitro and / or in vivo assays. For example, Fc receptor (FcR) binding assays can be performed to measure FcγR binding. NK cells, the primary cells mediating ADCC, express only FcγRIII, whereas monocytes express FcγRI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized in Ravetch and Kinet, Ann. Rev. Immunol., 1991, 9:457-492, which is incorporated by reference in its entirety.
[0264] Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are provided in U.S. Patent Nos. 5,500,362 and 5,821,337; Hellstrom et al., Proc. Natl. Acad. Sci. USA, 1986, 83:7059-7063; Hellstrom et al., Proc. Natl. Acad. Sci. USA, 1985, 82:1499-1502; and Bruggemann et al., J. Exp. Med., 1987, 166:1351-1361, each of which is incorporated by reference in its entirety. Effector cells useful in such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo using an animal model, such as that disclosed in Clynes et al. Proc. Natl. Acad. Sci. USA, 1998, 95:652-656, incorporated by reference in its entirety.
[0265]
[0265] A C1q binding assay can be performed to confirm that the antibody is unable to bind C1q and therefore lacks CDC activity. Examples of C1q binding assays include those described in WO 2006 / 029879 and WO 2005 / 100402, each of which is incorporated by reference in its entirety.
[0266]
[0266] Examples of complement activation assays include those described in Gazzano-Santoro et al., J. Immunol. Methods, 1996, 202:163-171; Cragg et al., Blood, 2003, 101:1045-1052; and Cragg and Glennie, Blood, 2004, 103:2738-2743, each of which is incorporated by reference in its entirety.
[0267]
[0267] FcRn binding and in vivo clearance (half-life determination) can also be measured, for example, using the methods described in Petkova et al., Intl. Immunol., 2006, 18:1759-1769, which is incorporated by reference in its entirety.
[0268] 12. Preparation of Antibody Conjugates 12.1. Antigen preparation
[0268] The FOLR1 protein used to isolate the antibody may be intact FOLR1 or a fragment of FOLR1. The intact FOLR1 protein or a fragment of FOLR1 may be in the form of an isolated protein or a protein expressed by a cell. Other forms of FOLR1 useful for generating antibodies will be apparent to those skilled in the art.
[0269] Monoclonal antibodies Monoclonal antibodies can be obtained using the hybridoma method first described by Kohler et al., Nature, 1975, 256:495-497 (e.g., incorporated by reference in its entirety) and / or by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567, incorporated by reference in its entirety). Monoclonal antibodies can also be obtained using, for example, phage-based or yeast-based libraries. See, e.g., U.S. Pat. Nos. 8,258,082 and 8,691,730, each of which is incorporated by reference in its entirety.
[0270] In the hybridoma technique, a mouse or other suitable host animal is immunized to give rise to lymphocytes that produce or are capable of producing antibodies that specifically bind to the protein used for immunization. Alternatively, lymphocytes can be immunized ex vivo. The lymphocytes are then fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form hybridoma cells. See Goding JW, Monoclonal Antibodies: Principles and Practice 3, incorporated by reference in its entirety. rd ed. (1986) Academic Press, San Diego, CA.
[0271]
[0271] The hybridoma cells are seeded and grown in an appropriate culture medium containing one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyltransferase (HGPRT or HPRT), the culture medium for the hybridomas typically contains hypoxanthine, aminopterin and thymidine (HAT medium), substances that prevent the growth of HGPRT-deficient cells.
[0272] Useful myeloma cells are those that fuse efficiently, support stable high-level antibody production by selected antibody-producing cells, and are sensitive to culture conditions, such as the presence or absence of HAT medium. Of these, preferred myeloma cell lines are mouse myeloma lines, such as those derived from MOP-21 and MC-11 mouse tumors (available from the Salk Institute Cell Distribution Center, San Diego, CA) and SP-2 or X63-Ag8-653 cells (available from the American Type Culture Collection, Rockville, MD). Human myeloma and mouse-human heteromyeloma cell lines have also been described for the production of human monoclonal antibodies. See, for example, Kozbor, J. Immunol., 1984, 133:3001, which is incorporated by reference in its entirety.
[0273] After identification of hybridoma cells producing antibodies of the desired specificity, affinity and / or biological activity, selected clones can be subcloned by limiting dilution and grown by standard methods. See Goding, supra. Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. Additionally, hybridoma cells can be cultured in vivo as ascites tumors in animals.
[0274]
[0274] DNA encoding a monoclonal antibody can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that can specifically bind to genes encoding the heavy and light chains of the monoclonal antibody). Thus, hybridoma cells can serve as a useful source of DNA encoding antibodies with the desired characteristics. Once isolated, the DNA can be placed into an expression vector, which is then transfected into host cells that do not otherwise produce antibodies, such as bacteria (e.g., E. coli), yeast (e.g., Saccharomyces or Pichia species), COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells, to produce the monoclonal antibody.
[0275] 12.3. Humanized Antibodies
[0275] Humanized antibodies can be made by replacing most or all of the structural portions of a non-human monoclonal antibody with the corresponding human antibody sequences, resulting in a hybrid molecule in which only the antigen-specific variable portions, or CDRs, are composed of non-human sequences. Methods for obtaining humanized antibodies include, for example, those described in Winter and Milstein, Nature, 1991, 349:293-299; Rader et al., Proc. Nat. Acad. Sci. USA, 1998, 95:8910-8915; Steinberger et al., J. Biol. Chem., 2000, 275:36073-36078; Queen et al., Proc. Natl. Acad. Sci. USA, 1989, 86:10029-10033; and U.S. Pat. Nos. 5,585,089, 5,693,761, 5,693,762, and 6,180,370, each of which is incorporated by reference in its entirety.
[0276] Human Antibodies Human antibodies can be produced by various techniques known in the art, for example, by using genetically modified animals (e.g., humanized mice).See, for example, Jakobovits et al., Proc. Natl. Acad. Sci. USA, 1993, 90:2551; Jakobovits et al., Nature, 1993, 362:255-258; Bruggermann et al., Year in Immuno., 1993, 7:33; and U.S. Patent No. 5,591,669, U.S. Patent No. 5,589,369, and U.S. Patent No. 5,545,807, each of which is incorporated by reference in its entirety. Human antibodies can also be derived from phage display libraries (see, e.g., Hoogenboom et al., J. Mol. Biol., 1991, 227:381-388; Marks et al., J. Mol. Biol., 1991, 222:581-597; and U.S. Pat. Nos. 5,565,332 and 5,573,905, each of which is incorporated by reference in its entirety). Human antibodies can also be produced by in vitro activated B cells (see, e.g., U.S. Pat. Nos. 5,567,610 and 5,229,275, each of which is incorporated by reference in its entirety). Human antibodies can also be derived from yeast-based libraries (see, e.g., U.S. Pat. No. 8,691,730, each of which is incorporated by reference in its entirety).
[0277] 12.5. Conjugation
[0277] The antibody conjugate may be prepared by standard techniques. In certain embodiments, the antibody is contacted with a payload precursor under conditions suitable for forming a bond from the antibody to the payload to form an antibody-payload conjugate. In certain embodiments, the antibody is contacted with a linker precursor under conditions suitable for forming a bond from the antibody to the linker. The resulting antibody-linker is contacted with a payload precursor under conditions suitable for forming a bond from the antibody-linker to the payload to form an antibody-linker-payload conjugate. In certain embodiments, the payload precursor is contacted with a linker precursor under conditions suitable for forming a bond from the payload to the linker. The resulting payload-linker is contacted with an antibody under conditions suitable for forming a bond from the payload-linker to the antibody to form an antibody-linker-payload-conjugate. Linkers suitable for preparing antibody conjugates are disclosed herein, and exemplary conditions for conjugation are described in the Examples below.
[0278]
[0278] In some embodiments, the anti-FOLR1 conjugate is prepared by contacting an anti-FOLR1 antibody disclosed herein with a linker precursor having any of the structures (A) to (L). [ka] [ka] [ka] [ka]
[0279]
[0279] In some embodiments, the stereochemistry of the linker precursors identified as (A)-(L) is identified by the R and S designations of each chiral center from left to right as depicted in formulas (A1)-(L1) and (A2)-(L2) below. [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]
[0280] 13. Vectors, host cells and recombinant methods
[0280] Embodiments also provide isolated nucleic acids encoding anti-FOLR1 antibodies, vectors and host cells containing the nucleic acids, and recombinant techniques for producing the antibodies.
[0281] For recombinant production of an antibody, the nucleic acid encoding it can be isolated and inserted into a replicable vector for further cloning (i.e., amplification of the DNA) or for expression. In some embodiments, the nucleic acid can be generated by homologous recombination as described, for example, in U.S. Patent No. 5,204,244, which is incorporated by reference in its entirety.
[0282]
[0282] Many different vectors are known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence, for example, as described in U.S. Patent No. 5,534,615, which is incorporated by reference in its entirety.
[0283]
[0283] Illustrative examples of suitable host cells are provided below, and these host cells are not intended to be limiting.
[0284]
[0284] Suitable host cells include any prokaryotic (eg, bacterial), lower eukaryotic (eg, yeast), or higher eukaryotic (eg, mammalian) cell. Suitable prokaryotes include, for example, eubacteria, such as gram-negative or gram-positive organisms such as Enterobacteriaceae, such as Escherichia (E. coli), Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella (S. typhimurium), Serratia (S. marcescens), Shigella, Bacilli (B. subtilis and B. licheniformis), Pseudomonas (P. aeruginosa), and Streptomyces. A useful E. coli cloning host is E. coli 294, although other strains such as E. coli B, E. coli X1776, and E. coli W3110 are also suitable.
[0285] In addition to prokaryotes, eukaryotic microbes, such as filamentous fungi or yeast, are suitable cloning or expression hosts for anti-FOLR1 antibody-encoding vectors. Saccharomyces cerevisiae, or common baker's yeast, is a commonly used lower eukaryotic host microorganism. However, it has been shown that Spodoptera frugiperda (e.g., SF9), Schizosaccharomyces pombe, Kluyveromyces species (K. lactis, K. fragilis, K. bulgaricus, K. wickerhamii, K. waltii, K. drosophilarum, K. thermotolerans and K. marxianus), Yarrowia species, Pichia pastoris, Candida species (C. albicans, C. Several other genera, species and strains are also available and useful, such as Saccharomyces cerevisiae (S. albicans), Trichoderma reesei, Neurospora crassa, Schwanniomyces (S. occidentalis), and filamentous fungi, such as Penicillium, Tolypocladium, and Aspergillus (A. nidulans and A. niger).
[0286]
[0286] Useful mammalian host cells include COS-7 cells, HEK293 cells; baby hamster kidney (BHK) cells; Chinese hamster ovary (CHO); mouse Sertoli cells; African green monkey kidney cells (VERO-76), and the like.
[0287]
[0287] The host cells used to produce the anti-FOLR1 antibody of the present invention can be cultured in various media. For example, commercially available media such as Ham's F10, basal medium (MEM), RPMI-1640 and Dulbecco's modified Eagle's medium (DMEM) are suitable for culturing the host cells. In addition, media described in Ham et al., Meth. Enz., 1979, 58:44; Barnes et al., Anal. Biochem., 1980, 102:255; and U.S. Patent No. 4,767,704, U.S. Patent No. 4,657,866, U.S. Patent No. 4,927,762, U.S. Patent No. 4,560,655 and U.S. Patent No. 5,122,469 or WO 90 / 03430 and WO 87 / 00195 can be used. Each of the above references is incorporated by reference in its entirety.
[0288]
[0288] Any of these media may be supplemented as necessary with hormones and / or other growth factors (such as insulin, transferrin or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics, trace elements (usually defined as inorganic compounds present at final concentrations in the micromolar range) and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
[0289]
[0289] Culture conditions such as temperature, pH, etc. will be those previously used with the host cell selected for expression and will be apparent to one of skill in the art.
[0290]
[0290] When using recombinant techniques, antibodies can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If antibodies are produced intracellularly, as a first step, particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. For example, Carter et al. (Bio / Technology, 1992, 10:163-167) describes a procedure for isolating antibodies secreted into the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonyl fluoride (PMSF) for about 30 minutes. Cell debris can be removed by centrifugation.
[0291] In some embodiments, the antibody is produced in a cell-free system. In some aspects, the cell-free system is an in vitro transcription and translation system as described in Yin et al., mAbs, 2012, 4:217-225, which is incorporated by reference in its entirety. In some aspects, the cell-free system utilizes cell-free extracts from eukaryotic or prokaryotic cells. In some aspects, the prokaryotic cell is E. coli. Cell-free expression of antibodies can be useful, for example, when the antibody accumulates as insoluble aggregates within the cell or when the yield from periplasmic expression is low. Antibodies produced in a cell-free system can be deglycosylated depending on the source of the cells.
[0292]
[0292] If the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, such as, for example, an Amicon® or Millipore® Pellicon® ultrafiltration device. A protease inhibitor, such as PMSF, may be included in any of the foregoing steps to inhibit proteolysis, and antibiotics may be included to prevent the growth of adventitious contaminants.
[0293] The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis and affinity chromatography, with affinity chromatography being a particularly useful purification technique. The suitability of protein A as an affinity ligand depends on the type and isotype of any immunoglobulin Fc domain present in the antibody. Protein A can be used to purify human gamma 1, gamma 2 or gamma 4 heavy chain-based antibodies (Lindmark et al., J. Immunol. Meth., 1983, 62:1-13, incorporated by reference in its entirety). Protein G is useful for all mouse isotypes and human gamma 3 (Guss et al., EMBO J., 1986, 5:1567-1575, incorporated by reference in its entirety).
[0294]
[0294] The matrix to which the affinity ligand is attached is often agarose, although other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. H3 If it contains a domain, BakerBond ABX® resin is useful for purification.
[0295]
[0295] Other techniques for protein purification, such as fractionation on ion exchange columns, ethanol precipitation, reverse phase HPLC, chromatography on silica, chromatography on Heparin Sepharose®, chromatofocusing, SDS-PAGE and ammonium sulfate precipitation, are also available and can be applied by one of skill in the art.
[0296]
[0296] Following any preliminary purification steps, the mixture containing the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography, generally performed at a low salt concentration (e.g., about 0 to about 0.25 M salt) and using an elution buffer of about pH 2.5 to about 4.5.
[0297] 14. Pharmaceutical Compositions and Methods of Administration
[0297] The antibodies and antibody conjugates provided herein can be formulated into pharmaceutical compositions using methods available in the art and those disclosed herein. Any of the antibody conjugates provided herein can be provided in a suitable pharmaceutical composition and administered by a suitable route of administration.
[0298] The methods provided herein include administering a pharmaceutical composition comprising at least one antibody conjugate provided herein and one or more compatible, pharma- ceutically acceptable carriers. In this context, the term "pharmaceutical acceptable" means approved by a regulatory agency of the federal or state government or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals and, more particularly, in humans. The term "carrier" includes a diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete)), excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers may be sterile liquids, such as water and oils, including mineral oils, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like, animal, vegetable, or synthetic origin. When the pharmaceutical composition is administered intravenously, water may be used as a carrier. Saline solutions and aqueous dextrose and glycerol solutions may also be used as liquid carriers, particularly for injectable solutions. Examples of suitable pharmaceutical carriers are described in Martin, EW, Remington's Pharmaceutical Sciences.
[0299] In clinical practice, the pharmaceutical composition or antibody conjugate provided herein can be administered by any route known in the art.Exemplary administration routes include, but are not limited to, inhalation, intraarterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, pulmonary and subcutaneous routes.In some embodiments, the pharmaceutical composition or antibody conjugate provided herein is administered parenterally.
[0300]
[0300] The composition for parenteral administration may be an emulsion or a sterile solution. The parenteral composition may contain, for example, propylene glycol, polyethylene glycol, vegetable oil and injectable organic ester (for example, ethyl oleate). These compositions may also contain wetting agents, isotonicity agents, emulsifiers, dispersants and stabilizers. Sterilization may be carried out in several ways, for example, by using a bacteriological filter, by radiation or heat. The parenteral composition may also be prepared in the form of a sterile solid composition that can be dissolved in sterile water or any other injectable sterile medium when used.
[0301] In some embodiments, the compositions provided herein are pharmaceutical compositions or single unit dosage forms. The pharmaceutical compositions and single unit dosage forms provided herein comprise a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic antibody conjugates.
[0302]
[0302] The pharmaceutical composition may include one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and one skilled in the art can select a suitable pharmaceutical excipient. Non-limiting examples of suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, powder, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, nonfat dry milk, glycerol, propylene, glycol, water, ethanol, and the like. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art, including, but not limited to, the manner in which the dosage form is administered to a subject and the specific antibody in the dosage form. The composition or single unit dosage form may contain small amounts of wetting or emulsifying agents or pH buffering agents, if necessary. Thus, the pharmaceutical excipients provided below are intended to be exemplary and not limiting. Additional pharmaceutical excipients include, for example, those described in Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), which is incorporated by reference in its entirety.
[0303]
[0303] In some embodiments, the pharmaceutical composition includes an antifoaming agent. Any suitable antifoaming agent may be used. In some aspects, the antifoaming agent is selected from alcohol, ether, oil, wax, silicone, surfactant, and combinations thereof. In some aspects, the antifoaming agent is selected from mineral oil, vegetable oil, ethylene bisstearamide, paraffin wax, ester wax, fatty alcohol wax, long chain fatty alcohol, fatty acid soap, fatty acid ester, silicone glycol, fluorosilicone, polyethylene glycol-polypropylene glycol copolymer, polydimethylsiloxane-silicon dioxide, ether, octyl alcohol, capryl alcohol, sorbitan trioleate, ethyl alcohol, 2-ethylhexanol, dimethicone, oleyl alcohol, simethicone, and combinations thereof.
[0304]
[0304] In some embodiments, the pharmaceutical composition comprises a co-solvent. Illustrative examples of co-solvents include ethanol, poly(ethylene) glycol, butylene glycol, dimethylacetamide, glycerin, and propylene glycol.
[0305]
[0305] In some embodiments, the pharmaceutical composition comprises a buffer. Illustrative examples of buffering agents include acetate, borate, carbonate, lactate, malate, phosphate, citrate, hydroxide, diethanolamine, monoethanolamine, glycine, methionine, guar gum, and monosodium glutamate.
[0306]
[0306] In some embodiments, the pharmaceutical composition includes a carrier or filler. Illustrative examples of carriers or fillers include lactose, maltodextrin, mannitol, sorbitol, chitosan, stearic acid, xanthan gum, and guar gum.
[0307]
[0307] In some embodiments, the pharmaceutical composition comprises a surfactant. Illustrative examples of surfactants include d-alpha tocopherol, benzalkonium chloride, benzethonium chloride, cetrimide, cetylpyridinium chloride, docusate sodium, glyceryl behenate, glyceryl monooleate, lauric acid, macrogol 15 hydroxystearate, myristyl alcohol, phospholipids, polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxylglycerides, sodium lauryl sulfate, sorbitan esters, and vitamin E polyethylene (glycol) succinate.
[0308]
[0308] In some embodiments, the pharmaceutical composition comprises an anti-caking agent. Illustrative examples of anti-caking agents include calcium phosphate (tribasic), hydroxymethylcellulose, hydroxypropylcellulose, and magnesium oxide.
[0309]
[0309] Other excipients that may be used with the pharmaceutical composition include, for example, albumin, antioxidants, antibacterial agents, antifungal agents, bioabsorbable polymers, chelating agents, controlled release agents, diluents, dispersants, dissolution enhancers, emulsifiers, gelling agents, ointment bases, penetration enhancers, preservatives, solubilizers, solvents, stabilizers, and sugars. Specific examples of each of these agents are described, for example, in Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), The Pharmaceutical Press, which is incorporated by reference in its entirety.
[0310]
[0310] In some embodiments, the pharmaceutical composition comprises a solvent. In some aspects, the solvent is a saline solution, such as sterile isotonic saline or dextrose solution. In some aspects, the solvent is water for injection.
[0311] In some embodiments, the pharmaceutical composition is in particulate form, such as a microparticle or nanoparticle. The microparticles and nanoparticles can be formed from any suitable material, such as a polymer or lipid. In some aspects, the microparticle or nanoparticle is a micelle, liposome, or polymersome.
[0312] Further provided herein are anhydrous pharmaceutical compositions and dosage forms comprising antibody conjugates, as, in some embodiments, water can facilitate the degradation of some antibodies.
[0313]
[0313] Anhydrous pharmaceutical compositions and dosage forms provided herein can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms that include lactose and at least one active ingredient that includes a primary or secondary amine can be anhydrous if substantial contact with moisture and / or humidity during manufacturing, packaging, and / or storage is expected.
[0314]
[0314] Anhydrous pharmaceutical compositions can be prepared and stored in such a way that their anhydrous nature is maintained.Thus, anhydrous compositions can be packaged using materials known to prevent exposure to water so that they can be included in suitable formulary kits.Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
[0315]
[0315] The lactose-free compositions provided herein may contain excipients known in the art, such as those listed in the United States Pharmacopoeia (USP) SP(XXI) / NF(XVI). In general, lactose-free compositions contain active ingredients, binders / fillers and lubricants in pharma- ceutically compatible and pharma-ceutically acceptable amounts. An exemplary lactose-free dosage form contains active ingredients, microcrystalline cellulose, pregelatinized starch and magnesium stearate.
[0316] Also provided are pharmaceutical compositions and dosage forms that comprise one or more excipients that reduce the rate at which the antibody or antibody conjugate will decompose. Such excipients, referred to herein as "stabilizers," include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers.
[0317] 14.1. Parenteral Dosage Forms
[0317] In certain embodiments, a parenteral dosage form is provided. Parenteral dosage forms can be administered to a subject by various routes, including but not limited to subcutaneous, intravenous (including bolus injection), intramuscular and intraarterial. Because administration of parenteral dosage forms typically avoids the subject's natural defense against contaminants, they are typically sterile or can be sterilized before being administered to a subject. Examples of parenteral dosage forms include, but are not limited to, injectable solutions, dry products that can be dissolved or suspended in pharma-ceutically acceptable injection vehicles, injectable suspensions and emulsions.
[0318]
[0318] Suitable vehicles that can be used to provide parenteral dosage forms are well known to those skilled in the art.Examples include, but are not limited to, water for injection USP; aqueous vehicles such as, but not limited to, sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection and lactated Ringer's injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate and benzyl benzoate.
[0319]
[0319] Excipients that increase the solubility of one or more antibodies disclosed herein can also be incorporated into the parenteral dosage form.
[0320] 15. Therapeutic applications For therapeutic applications, the conjugates provided herein can be administered to mammals, generally humans, in pharma- cerebrospinal, subcutaneous, intraarticular, intrasynovial, intrathecal or intratumoral routes as a bolus or by continuous infusion over a period of time. The antibody conjugates are also suitably administered by peritumoral, intralesional or perilesional routes to exert local and systemic therapeutic effects. The intravenous route can be particularly useful, for example, in the treatment of ovarian tumors.
[0321] The antibody conjugates provided herein may be useful for treating any disease or condition in which folate receptor alpha (FOLR1) is implicated. In some embodiments, the disease or condition is a disease or condition that can be diagnosed by overexpression of folate receptor alpha. In some embodiments, the disease or condition is a disease or condition that can benefit from treatment with an anti-folate receptor alpha antibody. In some embodiments, the disease or condition is cancer.
[0322]
[0322] Any suitable cancer may be treated using the antibody conjugates provided herein. Exemplary suitable cancers include, for example, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), adrenal cortical carcinoma, anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, brain tumor, bile duct cancer, bladder cancer, bone cancer, breast cancer (including triple negative breast cancer or TNBC), bronchial tumor, cancer of unknown primary, cardiac tumor, cervical cancer, chordoma, colon cancer, colorectal cancer, craniopharyngioma, ductal carcinoma, embryonal tumor, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, familial carcinoma, and follicular carcinoma. Lopian tube carcinoma, fibrous histiocytoma, Ewing's sarcoma, eye cancer, germ cell tumors, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gestational trophoblastic disease, gliomas, head and neck cancer, hepatocellular carcinoma, histiocytosis, Hodgkin's lymphoma, hypopharyngeal cancer, intraocular melanoma, pancreatic islet cell tumors, Kaposi's sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, lip and oral cavity cancer, liver cancer, lobular carcinoma in situ, lung cancer, macroglobulinemia malignant fibrous histiocytoma, melanoma, Merkel cell carcinoma, mesothelioma, metastatic squamous cell neck cancer of unknown primary site, midline carcinoma involving the NUT gene, oral cavity cancer, multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides, myelodysplastic syndrome, myelodysplastic / myeloproliferative neoplasms, nasal and paranasal sinus cancer, nasopharyngeal carcinoma, neuroblastoma, non-small cell lung cancer (NSCLC), oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, papilloma, paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma , pituitary tumors, pleuropulmonary blastoma, primary central nervous system lymphoma, primary peritoneal cancer, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis and ureter cancer, retinoblastoma, rhabdoid tumor, salivary gland cancer, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumors, stomach cancer, T-cell lymphoma, teratoma, testicular cancer, pharyngeal cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer, and Wilms' tumor.
[0323] In some embodiments, the disease to be treated with the antibody conjugates provided herein is gastric cancer, colorectal cancer, renal cell carcinoma, cervical cancer, non-small cell lung cancer, ovarian cancer, uterine cancer, fallopian tube cancer, primary peritoneal cancer, uterine cancer, endometrial cancer, prostate cancer, breast cancer, head and neck cancer, brain cancer, liver cancer, pancreatic cancer, mesothelioma, and / or cancer of epithelial origin. In certain embodiments, the disease is colorectal cancer. In some embodiments, the disease is ovarian cancer. In some embodiments, the disease is breast cancer. In some embodiments, the disease is triple negative breast cancer (TNBC). In some embodiments, the disease is lung cancer. In some embodiments, the disease is non-small cell lung cancer (NSCLC). In some embodiments, the disease is head and neck cancer. In some embodiments, the disease is renal cell carcinoma. In some embodiments, the disease is brain cancer. In some embodiments, the disease is endometrial cancer.
[0324]
[0324] In certain embodiments of the present disclosure, the cancer is a solid tumor. For example, the cancer can be ovarian cancer, ovarian carcinoma, ovary cancer, endometrial cancer, endometrioid adenocarcinoma, fallopian tube cancer, or primary peritoneal cancer. In certain embodiments, the cancer is recurrent ovarian cancer. In certain embodiments, the cancer is refractory ovarian cancer. In certain embodiments, the cancer is recurrent / refractory ovarian cancer.
[0325]
[0325] In certain embodiments, the effectiveness of the methods herein (e.g., methods of modulating an immune response in an individual) can be assessed by measuring the biological activity of cancer cells present in a sample isolated from the individual being treated.
[0326] 16. Combination In certain embodiments, the anti-FOLR1 antibody conjugate is used in combination with a second therapeutic agent that modulates angiogenesis. The anti-FOLR1 antibody conjugate can be any anti-FOLR1 antibody conjugate described herein. In certain embodiments, the second therapeutic agent is a VEGF inhibitor. Useful VEGF inhibitors are described herein. In certain embodiments, the second therapeutic agent is GCSF. Useful GCSF is described herein. In certain embodiments, the anti-FOLR1 antibody conjugate is used in combination with a VEGF inhibitor and GCSF.
[0327]
[0327] In general, the anti-FOLR1 antibody conjugate and the second therapeutic agent are administered according to their own dose and schedule. Thus, in certain embodiments, the anti-FOLR1 antibody conjugate is administered at a dose and schedule deemed useful by a specialist. In certain embodiments, the second therapeutic agent is administered at a dose and schedule deemed useful by a specialist. In certain embodiments, the second therapeutic agent is administered according to its labeling instructions.
[0328] In certain embodiments, the anti-FOLR1 antibody conjugate and the additional therapeutic agent are administered sequentially in any order. As used herein, the terms "sequentially," "sequentially," and "sequentially" refer to administration of the anti-FOLR1 antibody conjugate after the additional therapeutic agent or administration of the additional therapeutic agent after the anti-FOLR1 antibody conjugate. For example, sequential administration may include administration of the anti-FOLR1 antibody conjugate in the absence of the additional therapeutic agent during an induction period (first-line therapy), followed by a post-induction treatment period including administration of the additional therapeutic agent. The method may further include a maintenance period including administration of the anti-FOLR1 antibody conjugate or the additional therapeutic agent, or both. Alternatively, sequential administration may include administration of the additional therapeutic agent in the absence of the anti-FOLR1 antibody conjugate during an induction period (first-line therapy), followed by a post-induction treatment period including administration of the anti-FOLR1 antibody conjugate. The method may further include a maintenance period including administration of the anti-FOLR1 antibody conjugate or the additional therapeutic agent, or both.
[0329] In certain embodiments, the anti-FOLR1 antibody conjugate and the additional therapeutic agent are administered simultaneously. As used herein, the terms "together," "simultaneously," and "concurrently" refer to the administration of the anti-FOLR1 antibody conjugate and the additional therapeutic agent during the same consultation or during the same period of treatment. For example, both the anti-FOLR1 antibody conjugate and the additional therapeutic agent can be administered during one or more of the induction period, treatment period, and maintenance period. However, simultaneous administration does not require that the anti-FOLR1 antibody conjugate and the additional therapeutic agent be present together in a single formulation or pharmaceutical composition, or that the anti-FOLR1 antibody conjugate and the additional therapeutic agent be administered at exactly the same time.
[0330] In certain embodiments, provided herein is a method for treating cancer that responds to the inhibition of FOLR1 activity, comprising administering to an individual an effective amount of a combination provided herein to treat the cancer that responds to the inhibition of FOLR1 activity.In certain embodiments, the cancer is ovarian cancer, such as those described herein.
[0331] In certain embodiments, provided herein is a method for treating cancer that is unresponsive to the inhibition of FOLR1 activity alone, comprising administering to such individual an effective amount of the combination provided herein to treat the cancer that is unresponsive to the inhibition of FOLR1 activity alone.In certain embodiments, the cancer is ovarian cancer, such as those described herein.
[0332] In certain embodiments, compositions and therapeutic formulations are provided that include a combination of any of the antibody conjugates provided herein with one or more second therapeutic agents, and methods of treatment that include administering such combinations to a subject in need thereof. In some embodiments, the second agent is a VEGF inhibitor. In some embodiments, the one or more VEGF inhibitors include an antibody that inhibits VEGF activity. In some embodiments, the one or more VEGF inhibitors are selected from bevacizumab (AVASTIN®) and bevacizumab biosimilars.In some embodiments, the bevacizumab biosimilar is selected from the group consisting of MVASI (ABP 215, Amgen), Zirabev (Pfizer), Bevax (BEVZ92, mAbxience), Lumiere (Elea), Apotex (Apobiologix), Equidacent (FKB238, AstraZeneca / Centus Biotherapeutics), Avegra (BCD-021, Biocad), BP 01 (Aurobindo Pharma), BCD500 (BIOCND), Krabeva (Biocon), BAT1706 (Bio-Thera Solutions), BXT-2316 (BioXpress Therapeutics), Bevaro (Cadila Pharmaceuticals), BI 695502 (Boehringer Ingelheim), CT-P16 (Celltrion), CHS-5217 (Coherus), DRZ_BZ (Dr Reddy's Laboratories), Cizumab (Hetero / Lupin), Byvasda (IBI305, Innovent Biologics), MIL60 (Mabworks), MYL 1402O (Mylan), ONS-1045 (Oncobiologics / Viropro), HD204 (Prestige Biopharma), Ankeda (QL1101, Qilu Pharmaceutical), Bevacirel (Reliance Life Sciences), Aybintio (SB8, Samsung Bioepis), Onbevzi (Samsung Bioepis), HLX04 (Shanghai Henlius) Biotech), TX16 (Tanvex BioPharma), MB02 (mAbxience), BI 695502 (Boehringer Ingelheim) and Oyavas (STADA).
[0333]
[0333] Examples of the second agent include erlotinib (Tarceva®, Genentech / OSI Pharm.), bortezomib (Velcade®, Millennium Pharm.), fulvestrant (Faslodex®, AstraZeneca), Sutent (SU11248, Pfizer), letrozole (Femara®, Novartis), imatinib mesylate (GLEEVEC®, Novartis), PTK787 / ZK 222584 (Novartis), oxaliplatin (Eloxatin®, Sanofi), 5-FU (5-fluorouracil), leucovorin, rapamycin (sirolimus, Rapamune®, Wyeth), lapatinib (Tykerb®, GSK572016, Glaxo Smith). Kline), lonafarnib (SCH 66336), sorafenib (BAY43-9006, Bayer Labs) and gefitinib (Iressa®, AstraZeneca), alkylating agents such as AG1478, AG1571 (SU 5271; Sugen), thiotepa and Cytoxan® cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, metoledopa and uredopa; ethylenimines and methylolmelamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylolmelamine; acetogenins (especially bullatacin and bullatacinone); camptothecins (including the synthetic analogue topotecan); bryostatins; kallistatins; CC-1065 (including its synthetic analogues adozelesin, carzelesin and bizelesin); cryptophycins (especially cryptophycin 1 and cryptophycin 8); dolastatins; duocarmycins (including synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictin; spongistatins;nitrogen mustards, such as chlorambucil, chromafazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, nobembikine, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; enediyne antibiotics, such as the calicheamicins, especially uncialamicin, calicheamicin gameol, and calicheamicin omegal (Angew Chem. Intl. Ed. Engl. (1994) 33:183-186); dynemicins, including dynemicin A; bisphosphonates such as clodronate; esperamicin; and neocarzinostatin chromophores and related enediyne antibiotic chromophores), aclacinomycin, actinomycin, anthramycin, azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, Adriamycin (doxorubicin), morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin, Antibiotics such as mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, porfiromycin, puromycin, keramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pladienolide B, pteropterin, and trimetrexate; purine analogues such as fludarabine, 6-mercaptopurine, thiamnipurine, and thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine;Androgens such as calcineurin, dromostalon propionate, epithiostanol, mepitiostane, and testolactone; antiadrenergics such as aminoglutethimide, mitotane, and trilostane; folic acid supplements such as folinic acid; aceglatone; aldophosphamide glycosides; aminolevulinic acid; eniluracil; amsacrine; bestravcil; bisantrene; edatrexate; defofamine; demecolcine; diazicon ;Eflornithine;Elliptinium acetate;Epothilone;Etoglucide;Gallium nitrate;Hydroxyurea;Lentinan;Lonidamine;Maytansinoids such as maytansine and ansamitocins;Mitoguazone;Mitoxantrone;Mopidamol;Nitracrine;Pentostatin;Phenamet;Pirarubicin;Rosoxantrone;Podophyllic acid;2-Ethylhydrazide;Procarbazine;PSK(R) polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; schizofuran; spirogermanium; tenuazonic acid; triazicon; 2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2 toxin, veracrine A, roridin A and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; e.g., Taxol® (paclitaxel; Bristol-Myers Squibb Oncology, Princeton, NJ), Abraxane® (Cremophor-free), albumin engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.) and Taxotere® (docetaxel); Rhone-Poulenc Rorer, Antony, Taxoids such as cefotaxime (France); chlorambucil; Gemzar® (gemcitabine); 6-thioguanine; mercaptopurine; methotrexate; platinum analogues such as cisplatin and carboplatin; vinblastine; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; Navelbine® (vinorelbine); Novantrone;Also included are, but are not limited to, teniposide; edatrexate; daunomycin; aminopterin; capecitabine (Xeloda®); ibandronic acid; CPT-11; the topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; and pharma- ceutically acceptable salts, acids, and derivatives of any of the above.
[0334] In some embodiments, the second therapeutic agent is granulocyte colony stimulating factor (GCSF). In some embodiments, the second therapeutic agent is a pegylated GCSF. In some embodiments, the second therapeutic agent is GCSF and is pegfilgrastim or filgrastim. In some embodiments, the second therapeutic agent is pegfilgrastim. The pegfilgrastim can be Neulasta® or a biosimilar. In some embodiments, the second therapeutic agent is filgrastim. The filgrastim can be Neupogen® or a biosimilar.
[0335] In some embodiments, the second therapeutic agent, GCSF, is administered simultaneously or sequentially with the first dose of the antibody conjugate. In some embodiments, the second therapeutic agent is a second therapeutic agent and is administered at least 7 days after administration of the first dose of the antibody conjugate. In some embodiments, the second therapeutic agent is a second therapeutic agent and is administered 8, 9, 10 or 11 days after administration of the first dose of the antibody conjugate. In some embodiments, the second therapeutic agent is a second therapeutic agent and is administered 8±2 days after administration of the first dose of the antibody conjugate. In some embodiments, the second therapeutic agent is a second therapeutic agent and is administered approximately 8 days after administration of the first dose of the antibody conjugate. In some embodiments, the second therapeutic agent is administered 8 days after administration of the first dose of the antibody conjugate.
[0336] In some embodiments, the GCSF is pegfilgrastim, which is administered as directed or deemed appropriate by a specialist. In certain embodiments, the dose of pegfilgrastim is 6 mg. In some embodiments, pegfilgrastim is administered once every 8-10 days for 1-5 cycles. In some embodiments, pegfilgrastim is administered once every 8-10 days for 1-3 cycles. In some embodiments, pegfilgrastim is administered once every 8-10 days for 1 cycle.
[0337] In some embodiments, the GCSF is filgrastim, which is administered as directed or deemed appropriate by a specialist. In certain embodiments, the first dose is administered at least 24 hours after administration of the first dose of the antibody conjugate. In some embodiments, the GCSF is filgrastim, and the dose is 5-10 μg / kg / day. In some embodiments, the GCSF is filgrastim, and the dose is 5 μg / kg / day. In some embodiments, the GCSF is filgrastim, and the dose is 5 μg / kg / day, and the patient is undergoing myelosuppressive chemotherapy or induction and / or consolidation chemotherapy for AML. In some embodiments, the GCSF is intravenous filgrastim, and the dose is 5 μg / kg / day, and the patient is undergoing myelosuppressive chemotherapy or induction and / or consolidation chemotherapy for AML. In some embodiments, the GCSF is subcutaneous filgrastim, the dose is 5 μg / kg / day, and the patient is undergoing myelosuppressive chemotherapy or induction and / or consolidation chemotherapy for AML. In some embodiments, the GCSF is filgrastim, the dose is 10 μg / kg / day. In some embodiments, the GCSF is filgrastim, the dose is 10 μg / kg / day, and the patient is undergoing bone marrow transplantation or autologous peripheral blood progenitor cell harvesting and therapy. In some embodiments, the GCSF is subcutaneous filgrastim, the dose is 10 μg / kg / day, and the patient is undergoing bone marrow transplantation. In some embodiments, the GCSF is intravenous filgrastim, the dose is 10 μg / kg / day, and the patient is undergoing autologous peripheral blood progenitor cell harvesting and therapy. In some embodiments, the GCSF is filgrastim, the dose is 6 μg / kg / day. In some embodiments, the GCSF is filgrastim, the dose is 6 μg / kg / day, and the patient has congenital neutropenia.In some embodiments, the GCSF is subcutaneous filgrastim, the dose is 6 μg / kg / day, and the patient has congenital neutropenia.In some embodiments, the GCSF is filgrastim, the dose is 5 μg / kg / day, and the patient has cyclic or idiopathic neutropenia. In some embodiments, the GCSF is subcutaneous filgrastim, the dose is 5 μg / kg / day, and the patient has cyclic or idiopathic neutropenia. In some embodiments, the GCSF is filgrastim, the dose is 10 μg / kg / day, and the patient has been acutely exposed to a myelosuppressive dose of radiation. In some embodiments, the GCSF is subcutaneous filgrastim, the dose is 10 μg / kg / day, and the patient has been acutely exposed to a myelosuppressive dose of radiation.
[0338] 17. Kit
[0338] In some embodiments, the combinations provided herein are provided in the form of a kit, i.e., a packaged combination of reagents in predetermined amounts and instructions for performing the procedure. In other embodiments, the procedure is a therapeutic procedure.
[0339]
[0339] In some embodiments, the kit further comprises a solvent for reconstitution of the anti-FOLR1 antibody conjugate. In some embodiments, the anti-FOLR1 antibody conjugate is provided in the form of a pharmaceutical composition.
[0340] In some embodiments, the kit further comprises a VEGF inhibitor, such as bevacizumab or a bevacizumab biosimilar, and instructions for use. In certain embodiments, the kit provides a GCSF, such as pegfilgrastim or filgrastim, and instructions for use. In certain embodiments, the kit provides pegfilgrastim and instructions for use. In certain embodiments, the kit provides filgrastim and instructions for use.
[0341] In some embodiments, the kit further comprises instructions for use with a VEGF inhibitor, such as bevacizumab or a bevacizumab biosimilar. In certain embodiments, the kit provides instructions for use with a GCSF, such as pegfilgrastim or filgrastim. In certain embodiments, the kit provides instructions for use with pegfilgrastim. In certain embodiments, the kit provides instructions for use with filgrastim.
[0342]
[0342] In certain embodiments, the pharmaceutical package or kit comprises a container, a composition comprising a folate receptor alpha (FOLR1) antibody conjugate; and a package insert comprising instructions for administering the FOLR1 antibody conjugate according to the methods described herein. EXAMPLES
[0343] Working Example Example 1 Anti-FOLR1 in patients with ovarian cancer This study evaluated the pharmacokinetics, safety and efficacy of Conjugate A when given intravenously (IV) for the treatment of advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancer). Patients included individuals with recurrent platinum-resistant ovarian cancer or other high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer.
[0344]
[0344] Patients include those with low-grade ovarian cancer (grade 1); clear cell, mucinous, endometrioid, sarcomatoid and mixed histology ovarian cancer and sarcomatoid ovarian cancer; prior treatment with ADCs including ADC-targeted FolRα or tubulin inhibitors; prior anti-cancer therapy (prior to first dose of investigational drug): chemotherapy within 3 weeks, PARP inhibitor within 2 weeks, other therapeutic anti-cancer antibody within 3 weeks, radioactive - or toxin - within 10 weeks. including radiation therapy / major surgery within 4 weeks of the first dose of immunoconjugate (e.g., ADC) or investigational drug; pre-existing clinically significant eye disorder; prior solid organ transplant; ileus and / or signs / symptoms of ileus within the preceding 3 months; history of gastrointestinal perforation; residual CTCAE ≥ grade 2 toxicity from prior anticancer therapy; history of significant congestive heart failure; nephrotic syndrome; sensory or motor neuropathy grade >1; potentially life-threatening concurrent or recent malignancy; chronic or ongoing active infection requiring systemic treatment; ongoing immunosuppressive therapy, including systemic corticosteroids; clinically significant cardiac disease; renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease. Patients were excluded if they had any number of conditions, including, but not limited to, significant concurrent and uncontrolled medical conditions; history or clinical signs of meningeal or active central nervous system involvement; known severe chronic obstructive pulmonary disease or asthma (defined as FEV1 < 40% predicted) or active pneumonia within 6 months of the first dose of investigational drug; history of significant cerebrovascular disease, e.g., stroke or TIA, within 6 months; known human immunodeficiency virus seropositivity; pregnancy or breastfeeding; hepatitis B seropositivity defined by a positive HBsAg test; concurrent participation in another therapeutic trial; evidence of rectal-sigmoid involvement by pelvic exam or intestinal involvement on CT scan; history of hemoptysis within 6 months; or venous or arterial thromboembolic event within 3 months.
[0345] The initial dose of conjugate A was 4.3 mg / kg or 5.2 mg / kg. Dosing was given every 3 weeks. Certain patients who started on the 5.2 mg / kg dose were then switched to the 4.3 mg / kg dose after 2 or 3 cycles of the initial dose.
[0346] Patients are monitored to assess and determine adverse events, overall response rate (ORR), duration of response (DOR), overall survival (OS) and progression-free survival (PFS). Patients are monitored for potential drug-drug interactions.
[0347]
[0347] Figure 1 presents the maximum change in tumor target lesions across 33 patients. As of the analysis date, seven had confirmed partial responses and five had unconfirmed partial responses. Figure 2 shows that when comparing initial doses of 5.2 mg / kg vs. 4.3 mg / kg, approximately twice as many patients (48% vs. 25%) had partial responses (confirmed or unconfirmed). Figure 3 presents the change in size of target lesions across 33 patients. Good tumor control was achieved in many patients. Figure 4 presents treatment durability across 43 patients. Patients were initially administered 4.3 mg / kg or 5.2 mg / kg conjugate A. Antitumor activity appeared to be potent after two cycles at 5.2 mg / kg. Patients whose doses were changed from 5.2 mg / kg to 4.3 mg / kg are shown. Dose reduction did not appear to affect the ability to maintain disease control. Patients who had partial responses are also shown. Figure 5 presents immunohistochemistry positivity across 22 patients. The intensity of FolR1 staining is scored from 0 (no staining) to 1+, 2+ or 3+ (highest intensity). TPS is the percentage of cells with staining of any intensity. The percentage score is IHC positive tumor cells / total tumor cells x 100%.
[0348]
[0348] In a dose expansion cohort of 28 patients with recurrent / relapsed platinum-resistant ovarian cancer, the preliminary response rate (including both confirmed and unconfirmed responses by RECIST v1.1) was 32%.
[0349] Example 2 Anti-FOLR1 in patients with ovarian cancer This study evaluates the pharmacokinetics, safety and efficacy of Conjugate A given intravenously (IV) for the treatment of advanced epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer). Patients include individuals with progressive recurrent and / or progressive disease.
[0350] The initial dose of conjugate A is 5.2 mg / kg or 4.3 mg / kg. Doses are given every 3 weeks. Pegfilgrastim is administered subcutaneously at 6 mg on day 8 ± 2 of the treatment cycle. Certain patients who start on the 5.2 mg / kg dose are switched to the 4.3 mg / kg dose after 1, or 2, or 3, or 4 cycles of the initial dose. Certain patients on the 4.3 mg / kg dose are switched to the 3.5 mg / kg dose after 1, or 2, or 3 cycles of the previous dose.
[0351]
[0351] Patients are monitored to assess adverse events, overall response rate (ORR), duration of response (DOR), overall survival (OS), and progression-free survival (PFS). Patients are monitored for potential drug-drug interactions.
[0352] Example 3
[0352] Table 5 provides the sequences referred to herein.
[0353] [Table 5]
[0354] [Table 6]
[0355] [Table 7]
[0356] [Table 8]
[0357] [Table 9]
[0358]
Table 10
[0359]
Table 11
[0360]
Table 12
[0361]
Table 13
[0362]
Table 14
[0363]
Table 15
[0364]
Table 16
[0365]
Table 17
[0366]
Table 18
[0367]
Table 19
[0368]
Table 20
[0369] Equivalent
[0353] The disclosure described above may encompass multiple different inventions with independent utility. Although each of these inventions has been disclosed in its preferred form, they should not be considered in a limiting sense, since many variations are possible on the specific embodiments thereof disclosed and illustrated herein. The subject matter of the invention includes all novel and non-obvious combinations and subcombinations of the various elements, features, functions and / or properties disclosed herein. The following claims specifically point out certain combinations and subcombinations that are considered novel and non-obvious. Inventions embodied in other combinations and subcombinations of features, functions, elements and / or properties may be claimed in this application, applications claiming priority from this application or related applications. Such claims are also considered to be encompassed by the subject matter of the invention of the present disclosure, regardless of whether they relate to different inventions or the same invention, and whether they are broader, narrower, equal or different in scope compared to the original claims.
[0370]
[0354] One or more features from any embodiment described in this specification or drawings may be combined with one or more features of any other embodiment described in this specification or drawings without departing from the scope of the present invention.
[0371]
[0355] All publications, patents and patent applications mentioned in this specification are incorporated herein by reference as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. Although the present invention has been described in some detail by way of illustrations and examples for the purpose of clarifying the understanding of the foregoing invention, it will be readily apparent to those skilled in the art that, in light of the teachings of the present invention, certain changes and modifications thereto may be made without departing from the spirit or scope of the appended claims.
Claims
1. 1. A method for treating or preventing cancer in a subject in need thereof, comprising: (a) 1 to 3 first doses of an antibody conjugate comprising an antibody that specifically binds to folate receptor alpha (FOLR1), the antibody being site-specifically linked to at least one payload moiety; and (b) then administering at least one to three second doses of the antibody conjugate; administering to the subject, wherein the second dose is lower than the first dose.
2. 1. A method of treating cancer in a subject in need thereof, comprising: administering to the subject a first dose of a folate receptor alpha (FOLR1) antibody conjugate, wherein the FOLR1 antibody conjugate comprises an antibody linked to at least one payload moiety, and wherein the first dose is about 5.2 mg / kg or 4.3 mg / kg; administering a second dose of the FOLR1 antibody conjugate to the subject; and wherein the second dose is administered after the first dose, the amount of the second dose being less than the amount of the first dose, and the first and second doses being administered at least about three weeks apart.
3. 1. A method of treating cancer in a subject in need thereof, comprising: administering to the subject a first dose of a folate receptor alpha (FOLR1) antibody conjugate, the FOLR1 antibody conjugate comprising an antibody linked to at least one payload moiety; administering a second dose of the FOLR1 antibody conjugate to the subject; and wherein the second dose is about 4.3 mg / kg or less, the second dose is administered after the first dose, the amount of the first dose is greater than the amount of the second dose, and the first dose is administered once every 3 weeks or more for 1 to 6 cycles.
4. 1. A method of treating cancer in a subject in need thereof, comprising: administering to the subject a first dose of a folate receptor alpha (FOLR1) antibody conjugate, the FOLR1 antibody conjugate comprising an antibody linked to at least one payload moiety; administering a second dose of the FOLR1 antibody conjugate to the subject; and wherein the second dose is administered after the first dose, the amount of the first dose being the same as or greater than the amount of the second dose, and a tumor tissue sample from the subject has a Tumor Proportion Score (TPS) of about 25% or greater, and the subject has at least 30% tumor reduction by volume 3 weeks after administration of the first dose.
5. The method of any one of claims 1 to 4, wherein the first dose is about 5.2 mg / kg.
6. 6. The method of any one of claims 1 to 5, wherein the second dose is selected from about 4.3 mg / kg or less, about 3.5 mg / kg or less, and about 2.9 mg / kg or less.
7. 7. The method of any one of claims 1 to 6, wherein the second dose is about 4.3 mg / kg, about 3.5 mg / kg, or about 2.9 mg / kg.
8. 8. The method of any one of claims 1 to 7, wherein the first dose is about 5.2 mg / kg and the second dose is about 4.3 mg / kg; or the first dose is about 5.2 mg / kg and the second dose is about 3.5 mg / kg; or the first dose is about 5.2 mg / kg and the second dose is about 2.9 mg / kg; or the first dose is about 4.3 mg / kg and the second dose is about 3.5 mg / kg; or the first dose is about 4.3 mg / kg and the second dose is about 2.9 mg / kg.
9. 9. The method of any one of claims 1 to 8, wherein the first dose is administered once every 3 or more weeks for 1 to 5 cycles.
10. 10. The method of claim 9, wherein the first dose is administered for 1 to 3 cycles.
11. 10. The method of claim 9, wherein the first dose is administered for 2 to 4 cycles.
12. The method of any one of claims 1 to 11, wherein the second dose is administered at least about 3 weeks after the first dose is administered.
13. The method of any one of claims 1 to 12, wherein the second dose is administered at least about 6 weeks after the first dose is administered.
14. The method of any one of claims 1 to 13, wherein the second dose is administered at least about 6 weeks after the first dose is administered.
15. 15. The method of any one of claims 1 to 14, wherein the second dose is administered once every three weeks.
16. 16. The method of any one of claims 1-15, wherein the second dose is administered once every three weeks for at least about three weeks.
17. 16. The method of any one of claims 1-15, wherein the second dose is administered once every three weeks for at least about two months.
18. 16. The method of any one of claims 1-15, wherein the second dose is administered once every three weeks for at least about three months.
19. 16. The method of any one of claims 1-15, wherein the second dose is administered once every three weeks for at least about four months.
20. 16. The method of any one of claims 1-15, wherein the second dose is administered once every three weeks for the remainder of the treatment.
21. 5. The method of any one of claims 1 to 4, wherein the first dose and the second dose are administered at least about 3 weeks apart.
22. The method of any one of claims 1 to 21, further comprising administering a third dose of the FOLR1 antibody conjugate.
23. 23. The method of claim 22, wherein the amount of the third dose is less than the amount of the second dose.
24. 24. The method of claim 22 or 23, wherein the amount of the third dose is about 3.5 mg / kg or less or about 2.9 mg / kg or less.
25. 24. The method of claim 23, wherein the amount of the third dose is about 3.5 mg / kg or about 2.9 mg / kg.
26. The method of any one of claims 1 to 25, wherein the FOLR1 antibody conjugate is administered intravenously.
27. The method of any one of claims 1 to 26, wherein the antibody is site-specifically linked to at least one payload.
28. 28. The method of any one of claims 1-27, wherein the antibody comprises one or more unnatural amino acids at a site selected from the group consisting of HC F404, HC-K121, HC-Y180, HC-F241, HC-221, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, or HC-S70 according to the Kabat, Chothia, or EU numbering schemes.
29. 29. The method of any one of claims 1-28, wherein the antibody comprises one or more unnatural amino acids at a site selected from the group consisting of HC-F404, HC-Y180, and LC-K42 according to the Kabat, Chothia, or EU numbering scheme.
30. The method of claim 29, wherein the antibody comprises an unnatural amino acid at position HC-F404.
31. The method of claim 29, wherein the antibody comprises an unnatural amino acid at position HC-F404.
32. 30. The method of claim 29, wherein the antibody comprises unnatural amino acids at positions HC-F404 and HC-Y180.
33. 33. The method of any one of claims 28-32, wherein the residue of the one or more unnatural amino acids is linked to the payload moiety via a hydrolytically stable linker.
34. 33. The method of any one of claims 28 to 32, wherein the residue of the one or more unnatural amino acids is linked to the payload moiety via a cleavable linker.
35. 35. The method of any one of claims 28-34, wherein the one or more unnatural amino acids are selected from the group consisting of p-acetyl-L-phenylalanine, O-methyl-L-tyrosine, -3-(2-naphthyl)alanine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, tri-O-acetyl-GlcNAc P-serine, L-Dopa, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-azido-methyl-L-phenylalanine, compound 56, p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, L-phosphoserine, phosphonoserine, phosphonotyrosine, p-iodo-phenylalanine, p-bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, and p-propargyloxy-phenylalanine.
36. The method according to any one of claims 28 to 34, wherein the unnatural amino acid residue is a residue of compound (30) or compound (56).
37. 37. The method of any one of claims 1 to 36, wherein the at least one payload moiety is selected from the group consisting of maytansine, hemiasterlin, amanitin and auristatin.
38. 38. The method of any one of claims 1 to 37, wherein the at least one payload moiety is selected from the group consisting of DM1, hemiasterlin, amanitin, MMAF and MMAE.
39. The method of any one of claims 1 to 38, wherein the at least one payload moiety is a hemiasterlin derivative.
40. The at least one payload portion [Formula 1] where Ar is aryl or heteroaryl, L is a linker, and the wavy line indicates the bond to the antibody. The method according to any one of claims 1 to 39, wherein
41. The antibody is (i) V H Region SEQ ID NO: 362, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (ii) V H Region SEQ ID NO: 323, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (iii) V H Region SEQ ID NO: 308, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (iv) V H Region SEQ ID NO: 309, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (v) V H The three heavy chain CDRs and V of region SEQ ID NO: 310 L The three light chain CDRs of region SEQ ID NO:367; (vi) V H The three heavy chain CDRs and three light chain CDRs of region SEQ ID NO: 311 and V L The three light chain CDRs of region SEQ ID NO:367; (vii) V H The three heavy chain CDRs and V of region SEQ ID NO:312 L The three light chain CDRs of region SEQ ID NO:367; (viii) V H Region SEQ ID NO: 313, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (ix) V H Region SEQ ID NO: 314, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (x) V H Region SEQ ID NO: 315, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xi) V H Region SEQ ID NO: 316, the three heavy chain CDRs and V LThe three light chain CDRs of region SEQ ID NO:367; (xii) V H Region SEQ ID NO: 317, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xiii) V H Region SEQ ID NO: 318, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xiv) V H The three heavy chain CDRs and V of region SEQ ID NO: 319 L The three light chain CDRs of region SEQ ID NO:367; (xv) V H The three heavy chain CDRs and V of region SEQ ID NO: 320 L The three light chain CDRs of region SEQ ID NO:367; (xvi) V H Region SEQ ID NO: 321, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xvii) V H Region SEQ ID NO: 322, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xviii) V H Region SEQ ID NO: 324, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xix) V H Region SEQ ID NO: 325, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xx)V H Region SEQ ID NO: 326, the three heavy chain CDRs and V L The three light chain CDRs of the region SEQ ID NO: 367; or (xxi) V H Region SEQ ID NO: 327, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxii) V H Region SEQ ID NO: 328, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxiii) V H Region SEQ ID NO: 329, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxiv) V H Region SEQ ID NO: 330, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxv) V H Region SEQ ID NO: 331, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxvi) V H Region SEQ ID NO: 332, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxvii) V H Region SEQ ID NO: 333, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxviii) V H Region SEQ ID NO: 334, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxix) V H Region SEQ ID NO: 335, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxx)V H Region SEQ ID NO: 336, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxxi) V H The three heavy chain CDRs and V of region SEQ ID NO: 337 L The three light chain CDRs of region SEQ ID NO:367; (xxxii) V H Region SEQ ID NO: 338, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxxiii) V H Region SEQ ID NO: 339, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxxiv) V H Region SEQ ID NO: 340, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxxv)V H Region SEQ ID NO: 341 of the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxxvi)V H Region SEQ ID NO: 342, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxxvii) V H Region SEQ ID NO: 343, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxxviii)V H Region SEQ ID NO: 344, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xxxix)V H Region SEQ ID NO: 345, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xl) V H Region SEQ ID NO: 346, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xli) V H Region SEQ ID NO: 347, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xlii) V H Region SEQ ID NO: 348, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xliii) V H Region SEQ ID NO: 349 of the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xliv) V H Region SEQ ID NO: 350, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xlv) V H Region SEQ ID NO: 351, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xlvii) V H Region SEQ ID NO: 352, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xlvii) V H Region SEQ ID NO: 353, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xlviii) V H Region SEQ ID NO: 354, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (xlix)V H Region SEQ ID NO: 355, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (l) V H Region SEQ ID NO: 356, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (li) V H Region SEQ ID NO: 357, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (lii) V H Region SEQ ID NO: 358, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (liii) V H Region SEQ ID NO: 359, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (liv) V H Region SEQ ID NO: 360, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (lv) V H Region SEQ ID NO: 361, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:367; (lvi) V H Region SEQ ID NO: 363, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:368; (lvii) V HRegion SEQ ID NO: 364, the three heavy chain CDRs and V L The three light chain CDRs of region SEQ ID NO:368; (lviii) V H Region SEQ ID NO: 365, the three heavy chain CDRs and V L The three light chain CDRs of the region SEQ ID NO: 369; or (lix) V H Region SEQ ID NO: 366, the three heavy chain CDRs and V L Region SEQ ID NO: 369: 3 light chain CDRs The method of any one of claims 1 to 40, comprising:
42. The antibody is (i) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 58 and 117; a CDR-H2 comprising one of SEQ ID NOs: 176 and 235; and a CDR-H3 comprising SEQ ID NO: 294; (ii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 19 and 78; a CDR-H2 comprising one of SEQ ID NOs: 137 and 196; and a CDR-H3 comprising SEQ ID NO: 255; (iii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 4 and 63; a CDR-H2 comprising one of SEQ ID NOs: 122 and 181; and a CDR-H3 comprising SEQ ID NO: 240; (iv) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 5 and 64; a CDR-H2 comprising one of SEQ ID NOs: 123 and 182; and a CDR-H3 comprising SEQ ID NO: 241; (v) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 6 and 65; a CDR-H2 comprising one of SEQ ID NOs: 124 and 183; and a CDR-H3 comprising SEQ ID NO: 242; (vi) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 7 and 66; a CDR-H2 comprising one of SEQ ID NOs: 125 and 184; and a CDR-H3 comprising SEQ ID NO: 243; (vii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 8 and 67; a CDR-H2 comprising one of SEQ ID NOs: 126 and 185; and a CDR-H3 comprising SEQ ID NO: 244; (viii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 9 and 68; a CDR-H2 comprising one of SEQ ID NOs: 127 and 186; and a CDR-H3 comprising SEQ ID NO: 245; (ix) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 10 and 69; a CDR-H2 comprising one of SEQ ID NOs: 128 and 187; and a CDR-H3 comprising SEQ ID NO: 246; (x) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 11 and 70; a CDR-H2 comprising one of SEQ ID NOs: 129 and 188; and a CDR-H3 comprising SEQ ID NO: 247; (xi) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 12 and 71; a CDR-H2 comprising one of SEQ ID NOs: 130 and 189; and a CDR-H3 comprising SEQ ID NO: 248; (xii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 13 and 72; a CDR-H2 comprising one of SEQ ID NOs: 131 and 190; and a CDR-H3 comprising SEQ ID NO: 249; (xiii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 14 and 73; a CDR-H2 comprising one of SEQ ID NOs: 132 and 191; and a CDR-H3 comprising SEQ ID NO: 250; (xiv) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 15 and 74; a CDR-H2 comprising one of SEQ ID NOs: 133 and 192; and a CDR-H3 comprising SEQ ID NO: 251; (xv) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 16 and 75; a CDR-H2 comprising one of SEQ ID NOs: 134 and 193; and a CDR-H3 comprising SEQ ID NO: 252; (xvi) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 17 and 76; a CDR-H2 comprising one of SEQ ID NOs: 135 and 194; and a CDR-H3 comprising SEQ ID NO: 253; (xvii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 18 and 77; a CDR-H2 comprising one of SEQ ID NOs: 136 and 195; and a CDR-H3 comprising SEQ ID NO: 254; (xviii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 20 and 79; a CDR-H2 comprising one of SEQ ID NOs: 138 and 197; and a CDR-H3 comprising SEQ ID NO: 256; (xix) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 21 and 80; a CDR-H2 comprising one of SEQ ID NOs: 139 and 198; and a CDR-H3 comprising SEQ ID NO: 257; (xx) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 22 and 81; a CDR-H2 comprising one of SEQ ID NOs: 140 and 199; and a CDR-H3 comprising SEQ ID NO: 258; (xxi) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 23 and 82; a CDR-H2 comprising one of SEQ ID NOs: 141 and 200; and a CDR-H3 comprising SEQ ID NO: 259; (xxii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 24 and 83; a CDR-H2 comprising one of SEQ ID NOs: 142 and 201; and a CDR-H3 comprising SEQ ID NO: 260; (xxiii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 25 and 84; a CDR-H2 comprising one of SEQ ID NOs: 143 and 202; and a CDR-H3 comprising SEQ ID NO: 261; (xxiv) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 26 and 85; a CDR-H2 comprising one of SEQ ID NOs: 144 and 203; and a CDR-H3 comprising SEQ ID NO: 262; (xxv) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 27 and 86; a CDR-H2 comprising one of SEQ ID NOs: 145 and 204; and a CDR-H3 comprising SEQ ID NO: 263; (xxvi) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 28 and 87; a CDR-H2 comprising one of SEQ ID NOs: 146 and 205; and a CDR-H3 comprising SEQ ID NO: 264; (xxvii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 29 and 88; a CDR-H2 comprising one of SEQ ID NOs: 147 and 206; and a CDR-H3 comprising SEQ ID NO: 265; (xxviii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 30 and 89; a CDR-H2 comprising one of SEQ ID NOs: 148 and 207; and a CDR-H3 comprising SEQ ID NO: 266; (xxix) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 31 and 90; a CDR-H2 comprising one of SEQ ID NOs: 149 and 208; and a CDR-H3 comprising SEQ ID NO: 267; (xxx) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 32 and 91; a CDR-H2 comprising one of SEQ ID NOs: 150 and 209; and a CDR-H3 comprising SEQ ID NO: 268; (xxxi) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 33 and 92; a CDR-H2 comprising one of SEQ ID NOs: 151 and 210; and a CDR-H3 comprising SEQ ID NO: 269; (xxxii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 34 and 93; a CDR-H2 comprising one of SEQ ID NOs: 152 and 211; and a CDR-H3 comprising SEQ ID NO: 270; (xxxiii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 35 and 94; a CDR-H2 comprising one of SEQ ID NOs: 153 and 212; and a CDR-H3 comprising SEQ ID NO: 271; (xxxiv) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 36 and 95; a CDR-H2 comprising one of SEQ ID NOs: 154 and 213; and a CDR-H3 comprising SEQ ID NO: 272; (xxxv) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 37 and 96; a CDR-H2 comprising one of SEQ ID NOs: 155 and 214; and a CDR-H3 comprising SEQ ID NO: 273; (xxxvi) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 38 and 97; a CDR-H2 comprising one of SEQ ID NOs: 156 and 215; and a CDR-H3 comprising SEQ ID NO: 274; (xxxvii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 39 and 98; a CDR-H2 comprising one of SEQ ID NOs: 157 and 216; and a CDR-H3 comprising SEQ ID NO: 275; (xxxviii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 40 and 99; a CDR-H2 comprising one of SEQ ID NOs: 158 and 217; and a CDR-H3 comprising SEQ ID NO: 276; (xxxix) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 41 and 100; a CDR-H2 comprising one of SEQ ID NOs: 159 and 218; and a CDR-H3 comprising SEQ ID NO: 277; (xl) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 42 and 101; a CDR-H2 comprising one of SEQ ID NOs: 160 and 219; and a CDR-H3 comprising SEQ ID NO: 278; (xli) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 43 and 102; a CDR-H2 comprising one of SEQ ID NOs: 161 and 220; and a CDR-H3 comprising SEQ ID NO: 279; (xlii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 44 and 103; a CDR-H2 comprising one of SEQ ID NOs: 162 and 221; and a CDR-H3 comprising SEQ ID NO: 280; (xliii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 45 and 104; a CDR-H2 comprising one of SEQ ID NOs: 163 and 222; and a CDR-H3 comprising SEQ ID NO: 281; (xliv) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 46 and 105; a CDR-H2 comprising one of SEQ ID NOs: 164 and 223; and a CDR-H3 comprising SEQ ID NO: 282; (xlv) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 47 and 106; a CDR-H2 comprising one of SEQ ID NOs: 165 and 224; and a CDR-H3 comprising SEQ ID NO: 283; (xlvi) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 48 and 107; a CDR-H2 comprising one of SEQ ID NOs: 166 and 225; and a CDR-H3 comprising SEQ ID NO: 284; (xlvii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 49 and 108; a CDR-H2 comprising one of SEQ ID NOs: 167 and 226; and a CDR-H3 comprising SEQ ID NO: 285; (xlviii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 50 and 109; a CDR-H2 comprising one of SEQ ID NOs: 168 and 227; and a CDR-H3 comprising SEQ ID NO: 286; (xlix) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 51 and 110; a CDR-H2 comprising one of SEQ ID NOs: 169 and 228; and a CDR-H3 comprising SEQ ID NO: 287; (l) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 52 and 111; a CDR-H2 comprising one of SEQ ID NOs: 170 and 229; and a CDR-H3 comprising SEQ ID NO: 288; (li) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 53 and 112; a CDR-H2 comprising one of SEQ ID NOs: 171 and 230; and a CDR-H3 comprising SEQ ID NO: 289; (lii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 54 and 113; a CDR-H2 comprising one of SEQ ID NOs: 172 and 231; and a CDR-H3 comprising SEQ ID NO: 290; (liii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 55 and 114; a CDR-H2 comprising one of SEQ ID NOs: 173 and 232; and a CDR-H3 comprising SEQ ID NO: 291; (liv) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 56 and 115; a CDR-H2 comprising one of SEQ ID NOs: 174 and 233; and a CDR-H3 comprising SEQ ID NO: 292; (lv) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 57 and 116; a CDR-H2 comprising one of SEQ ID NOs: 175 and 234; and a CDR-H3 comprising SEQ ID NO: 293; (lvi) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 59 and 118; a CDR-H2 comprising one of SEQ ID NOs: 177 and 236; and a CDR-H3 comprising SEQ ID NO: 295; (lvii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 60 and 119; a CDR-H2 comprising one of SEQ ID NOs: 178 and 237; and a CDR-H3 comprising SEQ ID NO: 296; (lviii) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 61 and 120; a CDR-H2 comprising one of SEQ ID NOs: 179 and 238; and a CDR-H3 comprising SEQ ID NO: 297; or (lix) a VH comprising a CDR-H1 comprising one of SEQ ID NOs: 62 and 121; a CDR-H2 comprising one of SEQ ID NOs: 180 and 239; and a CDR-H3 comprising SEQ ID NO: 298 The method of any one of claims 1 to 41, comprising:
43. The antibody is (a) a VL comprising a CDR-L1 comprising SEQ ID NO: 300; a CDR-L2 comprising SEQ ID NO: 303; and a CDR-L3 comprising SEQ ID NO: 306; or (b) a VL comprising a CDR-L1 comprising SEQ ID NO: 301; a CDR-L2 comprising SEQ ID NO: 304; and a CDR-L3 comprising SEQ ID NO: 307 The method of any one of claims 1 to 42, comprising:
44. The antibody is (i) the VH region SEQ ID NO: 362 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (ii) the VH region SEQ ID NO: 323 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (iii) the VH region SEQ ID NO: 308 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (iv) the VH region SEQ ID NO: 309 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (v) the VH region SEQ ID NO: 310 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (vi) the VH region SEQ ID NO: 311 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (vii) the VH region SEQ ID NO: 312 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (viii) the VH region SEQ ID NO: 313 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (ix) the VH region SEQ ID NO: 314 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (x) the VH region SEQ ID NO: 315 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xi) the VH region SEQ ID NO: 316 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xii) the VH region SEQ ID NO: 317 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xiii) the VH region SEQ ID NO: 318 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xiv) the VH region SEQ ID NO: 319 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xv) the VH region SEQ ID NO: 320 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xvi) the VH region SEQ ID NO: 321 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xvii) the VH domain SEQ ID NO: 322 or a variant thereof and the VL domain SEQ ID NO: 367 or a variant thereof; (xviii) the VH domain SEQ ID NO: 324 or a variant thereof and the VL domain SEQ ID NO: 367 or a variant thereof; (xix) the VH region SEQ ID NO: 325 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xx) the VH region SEQ ID NO: 326 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; or (xxi) the VH region SEQ ID NO: 327 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xxii) the VH region SEQ ID NO: 328 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xxiii) the VH region SEQ ID NO: 329 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xxiv) the VH region SEQ ID NO: 330, or a variant thereof, and the VL region SEQ ID NO: 367, or a variant thereof; (xxv) the VH region SEQ ID NO: 331 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xxvi) the VH domain SEQ ID NO: 332 or a variant thereof and the VL domain SEQ ID NO: 367 or a variant thereof; (xxvii) the VH domain SEQ ID NO: 333 or a variant thereof and the VL domain SEQ ID NO: 367 or a variant thereof; (xxviii) the VH domain SEQ ID NO: 334 or a variant thereof and the VL domain SEQ ID NO: 367 or a variant thereof; (xxix) the VH region SEQ ID NO: 335 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xxx) the VH region SEQ ID NO: 336 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xxxi) the VH region SEQ ID NO: 337 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xxxii) the VH region SEQ ID NO: 338 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xxxiii) the VH region SEQ ID NO: 339 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xxxiv) the VH region SEQ ID NO: 340, or a variant thereof, and the VL region SEQ ID NO: 367, or a variant thereof; (xxxv) the VH region SEQ ID NO: 341 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xxxvi) the VH domain SEQ ID NO: 342 or a variant thereof and the VL domain SEQ ID NO: 367 or a variant thereof; (xxxvii) the VH domain SEQ ID NO: 343 or a variant thereof and the VL domain SEQ ID NO: 367 or a variant thereof; (xxxviii) the VH domain SEQ ID NO: 344 or a variant thereof and the VL domain SEQ ID NO: 367 or a variant thereof; (xxxix) the VH region SEQ ID NO: 345 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xl) the VH region SEQ ID NO: 346 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xli) the VH region SEQ ID NO: 347 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xlii) the VH region SEQ ID NO: 348 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xliii) the VH domain SEQ ID NO: 349 or a variant thereof and the VL domain SEQ ID NO: 367 or a variant thereof; (xliv) the VH region SEQ ID NO: 350 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xlv) the VH region SEQ ID NO: 351 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xlvi) the VH region SEQ ID NO: 352 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xlvii) the VH region SEQ ID NO: 353 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (xlviii) the VH domain SEQ ID NO: 354 or a variant thereof and the VL domain SEQ ID NO: 367 or a variant thereof; (xlix) the VH region SEQ ID NO: 355 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (l) the VH region SEQ ID NO: 356 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (li) the VH region SEQ ID NO: 357 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (lii) the VH region SEQ ID NO: 358 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (liii) the VH region SEQ ID NO: 359 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (liv) the VH region SEQ ID NO: 360 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (lv) the VH region SEQ ID NO: 361 or a variant thereof and the VL region SEQ ID NO: 367 or a variant thereof; (lvi) the VH region SEQ ID NO: 363 or a variant thereof and the VL region SEQ ID NO: 368 or a variant thereof; (lvii) the VH region SEQ ID NO: 364 or a variant thereof and the VL region SEQ ID NO: 368 or a variant thereof; (lviii) the VH domain SEQ ID NO: 365 or a variant thereof and the VL domain SEQ ID NO: 369 or a variant thereof; or (lix) VH region SEQ ID NO: 366 or a variant thereof and VL region SEQ ID NO: 369 or a variant thereof The method of any one of claims 1 to 43, comprising:
45. The antibody conjugate comprises conjugate P: [chemical 2] (wherein n is an integer from 1 to 6). The method of any one of claims 1 to 44, having the structure:
46. The antibody conjugate comprises conjugate M: [C3] (wherein n is an integer from 1 to 6). The method of any one of claims 1 to 45, having the structure:
47. The antibody conjugate comprises conjugate Q: [C4] (wherein n is an integer from 1 to 6). The method of any one of claims 1 to 46, having the structure:
48. 48. The method of any one of claims 1 to 47, wherein the antibody comprises a VH region of SEQ ID NO: 362 or a variant thereof having seven or fewer amino acid substitutions and a VL region of SEQ ID NO: 367 or a variant thereof having seven or fewer amino acid substitutions.
49. The method of any one of claims 1 to 48, wherein the antibody comprises a VH region of SEQ ID NO: 323 or a variant thereof having seven or fewer amino acid substitutions and a VL region of SEQ ID NO: 367 or a variant thereof having seven or fewer amino acid substitutions.
50. 50. The method of any one of claims 1 to 49, wherein the amino acid substitutions are conservative amino acid substitutions.
51. The method of any one of claims 1 to 50, wherein the antibody further comprises at least one constant region domain.
52. 52. The method of claim 51 , wherein the constant region comprises a sequence selected from SEQ ID NOs: 370, 371 and 372.
53. 53. The method of claim 52, wherein the antibody constant region is according to SEQ ID NO:
370.
54. 53. The method of claim 52, wherein the antibody constant region is according to SEQ ID NO:
371.
55. 53. The method of claim 52, wherein the antibody constant region is according to SEQ ID NO:
372.
56. The method of any one of claims 1 to 55, wherein the antibody is a monoclonal antibody.
57. 57. The method of any one of claims 1 to 56, wherein the antibody is IgA, IgD, IgE, IgG or IgM.
58. The method of any one of claims 1 to 57, wherein the antibody is humanized or human.
59. The method of any one of claims 1 to 58, wherein the antibody is aglycosylated.
60. The method of any one of claims 1 to 59, wherein the antibody is an antibody fragment.
61. 61. The method of claim 60, wherein the antibody fragment is selected from an Fv fragment, a Fab fragment, an F(ab')2 fragment, a Fab' fragment, an scFv (sFv) fragment, and an scFv-Fc fragment.
62. 62. The method of claim 61 , wherein the antibody fragment is an scFv fragment.
63. The method of claim 61 , wherein the antibody fragment is an scFv-Fc fragment.
64. 64. The method of any one of claims 1 to 63, wherein the subject has previously undergone treatment for cancer.
65. 65. The method of any one of claims 1-64, wherein the subject has not previously undergone treatment for cancer.
66. The method of any one of claims 1 to 65, wherein the subject has been diagnosed with cancer.
67. 67. The method of any one of claims 1 to 66, wherein the cancer is ovarian cancer.
68. 68. The method of any one of claims 1 to 67, wherein the cancer is endometrial cancer.
69. The antibody conjugate comprises conjugate P: [C5] (Wherein, n is 4) having the structure: the antibody is an IgG antibody comprising a VH region according to SEQ ID NO: 362 and a VL region according to SEQ ID NO: 367; The antibody further comprises a para-azidomethylphenylalanine residue replacing Y180 and F404 of each VH region; and 69. The method of any one of claims 1 to 68, wherein each bond in the structure to the antibody is to one side chain of the para-azidomethylphenylalanine residue.
70. 70. The method of any one of claims 1 to 69, further comprising administering a second therapeutic agent.
71. 71. The method of claim 70, wherein the second therapeutic agent is granulocyte colony stimulating factor (GCSF).
72. 71. The method of claim 70, wherein the second therapeutic agent is pegylated GCSF.
73. 72. The method of claim 71, wherein the GCSF is pegfilgrastim or filgrastim.
74. 72. The method of claim 71, wherein the GCSF is pegfilgrastim.
75. 75. The method of any one of claims 70-74, wherein the second therapeutic agent is administered simultaneously or sequentially with the first dose of the antibody conjugate.
76. 75. The method of any one of claims 70-74, wherein the second therapeutic agent is administered at least 7 days after administration of the first dose of the antibody conjugate.
77. 75. The method of any one of claims 70-74, wherein the second therapeutic agent is administered 7, 8, 9, 10 or 11 days after administration of the first dose of the antibody conjugate.
78. 75. The method of any one of claims 70-74, wherein the second therapeutic agent is administered 8±2 days after administration of the first dose.
79. 75. The method of any one of claims 70-74, wherein the second therapeutic agent is administered approximately 8 days after administration of the first dose.
80. 75. The method of any one of claims 71 to 74, wherein the GCSF is pegfilgrastim and the dose is 6 mg.
81. 75. The method of any one of claims 70-74, wherein the second therapeutic agent is administered once every 8-10 days for 1-5 cycles.
82. 75. The method of any one of claims 70-74, wherein the second therapeutic agent is administered once every 8-10 days for 1-3 cycles.
83. 75. The method of any one of claims 70-74, wherein the second therapeutic agent is administered at least 24 hours after administration of the first dose of the antibody conjugate.
84. 74. The method of any one of claims 70 to 73, wherein the GCSF is filgrastim and the dose is 5 to 10 μg / kg / day.
85. container; A composition comprising a folate receptor alpha (FOLR1) antibody conjugate; and A package insert comprising instructions for administering the FOLR1 antibody conjugate according to the method of any one of claims 1 to 84. A pharmaceutical package or kit comprising:
86. A pharmaceutical package or kit further comprising instructions for administering the FOLR1 antibody conjugate in combination with a second therapeutic agent.
87. A pharmaceutical package or kit further comprising instructions for administering the FOLR1 antibody conjugate in combination with pegfilgrastim.
88. A pharmaceutical package or kit further comprising instructions for administering the FOLR1 antibody conjugate in combination with filgrastim.
